annual report access healthcare important lifechanging innovation meaningful reaches need put access core business consider key part commitment improving patient outcomes combined strengths diagnostics pharmaceuticals position us play decisive role along patients journey partner stakeholders address root causes global country community levels prevent access innovative healthcare matter people live rochecomaccesscontents shareholder letters business performance reporting strategy diagnostics pharmaceuticals personalised healthcare access healthcare people culture environment community engagement business ethics corporate governance remuneration report rochecomreportingletters shareholders years roche worked improve health countless people world trust shareholders guided scientific progress continue identify seize opportunities well futuredr christoph franz chairman basel switzerland final letter shareholders christoph franz reflects companys performance countless collaborations partners around world increase access healthcare everyoneletters shareholders roche dr severin schwan ceo roche group basel switzerland last time ceo severin schwan shares thoughts progress made patients society advances digital healthcare dr christoph franzchairmans shareholder letter roche dear shareholders company achieved good results even world improve access medicines last years challenging environment sales diagnostics thereby improve peoples lives increased net income amounted billion swiss francs board directors example partnership project proposes annual general meeting echo nonprofit organisation uses video dividend increased swiss telementoring medical education care francs per share nonvoting equity security management project connects national th increase succession centres excellence remote underserved areas giving patients access specialised care challenges past year otherwise wouldnt receive manifold particular war ukraine brought unimaginable suffering millions good healthcare lifesaving patients people massive impact creates enormous value society whole economy time people around imagine means person cancer world still preoccupied consequences cured thanks timely accurate diagnosis covid pandemic effective treatment continue around family well contributing connection war ukraine able society economy early diagnosis even experience particularly impressive way prevent illness altogether thus avoid costly employees fully committed providing patients hospital stays medicines diagnostic tests deeply grateful incredible helpfulness initiative hope access modern effective employees across borders healthcare one day possible everywhere world roche making significant currently roche total number new contribution compounds additional indications clinical development registration diagnostics final letter esteemed shareholders division also flourishing thanks continuous roche twelve years board development new innovative instruments directors including nine chairman tests confident decided stand reelection next future roche general meeting severin schwan designated new chairman board innovations reach people need directors thomas schinecker new ceo work healthcare partners within roche led future strong country roche engaged hundreds highly experienced team partnerships collaborations around unless otherwise stated growth rates comparisons previous year constant exchange rates cer average rates total figures quoted reported chf severin schwan thomas schinecker roche led future strong highly experienced team would like thank severin schwan great honour work sincerely outstanding achievements unique excellent company roches success ceo roche last years well due particular fact company always trusting respectful cooperation owned founders descendants severin schwan contributed decisively years owner families longterm orientation major success company would particularly enables leadership roche make right like highlight integration genentech decisions company continue milestone development roche equally make major contributions peoples health noteworthy fact pharmaceuticals many years ahead therefore thank owner business compensated loss families great support patent protection topselling medicines thanks introduction new innovative would also like particular thank roche products recent years employees significant medical advances achieved together thank much finally delighted able dear shareholders trust strengthen board directors roche two key personalities board directors propose mark schneider ceo nestl akiko iwasaki professor immunobiology molecular cellular developmental biology yale university researcher howard hughes medical institute annual general meeting election dr christoph franz new board members chairmanchairmans shareholder letter roche roche board directors december bernard poussot c e g dr jrg duschmal representative shareholder group pooled voting rights b e g dr christoph franz chairman c e g andr hoffmann vicechairman representative shareholder group pooled voting rights c e g dr severin schwan f dr claudia suessmuth dyckerhoff b e g dr patrick frost b c e g anita hauser e g prof dr richard p lifton c e g dr jemilah mahmood e g corporate governance sustainability committee b audit committee c remuneration committee chairmansnomination committee e nonexecutive director f executive director g independent member board directors committee chairperson thank much christoph franz years general meeting christoph franzs giving people worldwide access medicines many years work head company diagnostics always one come end twelve years board christoph franzs particular concerns directors nine years chairman christoph travels roche subsidiaries africa asia franz decided stand reelection south america therefore always took time visit local hospitals talk doctors doubt throughout tenure local nursing staff patients together outgoing chairman strongly influenced roches local government representatives effected strategic development made considerable remarkable number agreements personal contribution success roche governments around world company although joined roche elsewhere aim working together improve local christoph franz able make valuable healthcare systems contributions board directors outset undoubtedly result many personally always appreciated years experience international companies christoph franz wealth entrepreneurial together board directors experience wideranging knowledge executive committee simply manage advocated obvious solutions also problems tackled promptly provided particular challenging choices constructive solutions confidently still key safeguarding successfully steered company roches future challenging times great dedication examples would like mention include roches behalf entire board directors contribution pandemic handling oeri hoffmann duschmal families patent expiry three widely used would like sincerely thank chairman cancer medicines addition christoph franz made important contribution expanding roches strategic flexibility repurchasing roche shares held novartis since took top role roche digitalisation healthcare sector also accelerated alongside farreaching transformation company roche today andr hoffmann clearly different roche decade ago vicechairman board directorsletter vicechairman roche andr hoffmann dr severin schwanshareholder letter ceo roche group roche dear shareholders overall achieved good results last year another highlight cancer immunotherapy primarily due continued strong demand tecentriq also approved europe routine diagnostics newer medicines countries treatment early treat serious diseases multiple sclerosis stage lung cancer many people raises haemophilia severe eye diseases spinal muscular prospect cure atrophy cancer innovative research development development delivery pioneering carry opportunities also risks addition medicines diagnostics heart many successes also experienced setbacks mission innovations roche improve lives last year first foremost disappointing people worldwide billion tests study data gantenerumab treatment performed diagnostic products delivering alzheimers disease setbacks crucial information disease prevention diagnosis reason give part often long treatment millions patients treated iterative research development processes roche medicines industry learn study data implement lessons next study particularly pleased recent successes roche molecules alzheimers ophthalmology vabysmo novel treatment development continue certain severe eye diseases launched entrepreneurial courage invest particularly beginning large number patients highrisk research areas alzheimers already access innovative eye medicine hope ultimately achieve breakthrough vabysmo became one important growth patients drivers months innovative diagnostic solutions enable early last year also able provide patients reliable decisionmaking whether infectious two important medicines blood cancer diseases cancer diseases pcr lunsumio gives hope people certain form test kits developed record time detection follicular lymphoma blood cancer develops mpox virus proven slowly incurable new covid able respond quickly immunotherapy activates bodys immune new public health threats system promising new approach blood cancer polivy significantly improves chances curing certain human papillomaviruses hpv may particularly aggressive form blood cancer cause cervical cancer new hpv selfsampling two decades research area made little solution offers women possibility take progress real medical breakthrough cervical samples needed hpv testing roche corporate executive committee december dr alan hippe chief financial information officer claudia bckstiegel general counsel dr aviv regev head genentech research early development gred prof dr hans clevers head roche pharma research early development pred dr severin schwan ceo roche group cristina wilbur chief people officer bill anderson ceo roche pharmaceuticals barbara schdler head group communications dr james h sabry global head pharma partnering dr thomas schinecker ceo roche diagnostics member enlarged corporate executive committeeshareholder letter ceo roche group roche particularly pleased brought two new medicines patients vabysmo certain severe eye diseases lunsumio currently incurable form blood cancer healthcare facility diagnostics digital solutions one roof solution help break barriers screening roche well positioned perform pioneering cervical cancer new hcv duo assay work field first time also help prevent cancer well diseases year history caused hepatitis c assay provides antigen antibody results one test thus would like thank employees helping diagnose hepatitis c faster tireless commitment challenging year also expanded digital would like thank chairman christoph health business example new digital franz many years confidenceinspiring solution pathology delivers highresolution work always passionate ensuring digital images tissue samples even faster products solutions reach people evaluation carried using microscope desperately need matter live electronically artificial intelligence often sees human eye makes easier thomas schinecker take role ceo diagnose cancer enables targeted midmarch would like thank effective treatment patient concerned outstanding work head diagnostics division look forward continue working fragmented healthcare systems medical knowledge often untapped today inadequate digitalisation thats thank dear shareholders trust cloudbased platform cobas infinity edge comes company play enables nursing staff doctors securely share patient data multiple sources brings together range health data electronic patient records thirdparty apps pointofcare services digital transformation bringing huge dr severin schwan advances patients pharmaceuticals ceo roche groupbusiness performance roche business performance achieved good results expected demand covid products declined diagnostics base business newer medicines continued strong growth un sdgs material topic longterm mindset key figures chf millions group sales pharmaceuticals sales diagnostics sales core operating profit rd core investments chf dividend unless otherwise stated growth rates comparisons previous year constant exchange rates cer average rates total figures quoted reported chfbusiness performance roche diagnostics pharmaceuticals employees operating divisional group corporate chugai research development sites pharmaceuticals manufacturing sites pharmaceuticals diagnostics worldwide diagnostics worldwide million patients roche medicines treated roche medicines model list essential medicines number employees expressed fulltime equivalents roche group roche sales rose chf expected impact biosimilars chf billion core operating profit increased sales cancer medicines mabtherarituxan chf reflecting good underlying herceptin avastin continued slow business performance resulted combined chf billion reduction sales ifrs net income chf billion decreasing compared due higher diagnostics division increased sales impairments intangible assets higher interest chf billion divisions base business costs income taxes achieved good results year across regions growth mainly driven core earnings per share grew chf immunodiagnostic products includes positive impact repurchase roche shares held novartis broad portfolio covid tests generated sales totalling chf billion compared pharmaceuticals division sales increased chf billion chf billion newer medicines treat severe diseases continued strong growth vabysmo outlook eye medicine launched beginning due sharp decline sales covid already one top five growth drivers products roughly chf billion roche expects medicine together ocrevus multiple sclerosis decrease group sales low single digit hemlibra haemophilia evrysdi spinal muscular range constant exchange rates excluding atrophy tecentriq cancer generated covid sales decline roche anticipates solid additional sales totalling chf billion underlying sales growth divisions sales covid medicines generally core earnings per share targeted develop lower decline roughly chf billion broadly line sales decline constant decrease sales actemraroactemra exchange rates roche expects increase severe covid pneumonia partially dividend swiss francs made sales growth ronapreve highrisk patients japan unless otherwise stated growth rates comparisons previous year constant exchange rates cer average rates total figures quoted reported chf ifrs result includes noncore items global restructuring plans amortisation impairment goodwill intangible assetsbusiness performance roche roche group pharmaceuticals division sales chf millions diagnostics division diagnostics diagnostics division sales grew emergency rooms medical practices directly chf billion divisions base business patients includes sarscov rapid tests achieved good results year blood gas electrolyte tests across regions growth mainly driven immunodiagnostic products molecular lab sales decreased due lower covidrelated sales north america broad portfolio covid tests generated emea regions partly offset sales totalling chf billion compared growth base business across portfolio chf billion customer area focuses molecular labs sales asiapacific north america regions provides diagnostics solutions pathogen increased respectively detection monitoring donor screening sexual drop sales europe middle east africa health genomics emea region primarily due reduced demand covid testing diabetes care sales decreased due base effect resolution rebate dispute core lab sales increased immunoassays excluding effect sales remained stable cardiac oncology tests clinical continued contraction blood glucose chemistry products main growth drivers monitoring market particular united states sales grew across regions strongly europe offset higher demand asiapacific emea latin america emerging markets customer area focuses central labs customer area focuses integrated provides diagnostics solutions personalised diabetes management people areas immunoassays clinical chemistry diabetes healthcare professionals custom biotech pathology lab sales increased due point care sales grew sarscov growth advanced staining rapid antigen test continued main companion diagnostics businesses sales growth driver demand cobas sarscov grew across regions influenza ab assays also increased largest contribution came asiapacific customer area focuses pathology labs north america regions provides diagnostics solutions tissue biopsies companion diagnostics customer area provides diagnostics solutions targeted diagnostics support specific immediately point care therapy decisions patientbusiness performance roche sales customer area chf millions core lab point care molecular lab diabetes care pathology lab pharmaceuticals pharmaceuticals division sales increased indications remained strong united chf billion newer medicines treat severe states europe international region diseases continued strong growth medicine continued show high uptake sales united states decreased slightly perjeta chf billion herpositive sales growth newer medicines breast cancer sales increased mostly due ocrevus vabysmo hemlibra tecentriq partially continuing high demand international region compensated sales decline actemra mainly china roactemra covid medicines whose patents expired hemlibra chf billion haemophilia without factor viii inhibitors europe sales also slightly prophylactic treatment administered mainly due lower sales covid medicine subcutaneously weekly every two every ronapreve excluding base effect sales four weeks sales continued show impressive europe increased newer medicines uptake especially united states europe offset impact biosimilars sales international region grew across major markets sales japan increased substantial key factors supplies ronapreve tecentriq chf billion cancer government followed sales growth evrysdi immunotherapy either alone combinations polivy hemlibra enspryng various types cancer eg lung bladder offset impact biosimilars government breast liver cancer sales increased mostly price cuts due higher demand united states europe sales japan decreased primarily due sales international region grew governmental price cuts china sales decreased due biosimilars lower sales rocephin local covid actemraroactemra chf billion measures excluding china sales region rheumatoid arthritis forms juvenile idiopathic increased mainly result higher arthritis giant cell arteritis car tcellinduced demand perjeta hemlibra ocrevus kadcyla severe lifethreatening cytokine release syndrome covid sales decreased mainly ocrevus chf billion relapsing united states international region primary progressive forms multiple sclerosis driven lower demand patients severe twohouronly infusion demand ocrevus covid pneumoniabusiness performance roche topselling pharmaceuticals chf millions ocrevus neuroscience perjeta oncology hemlibra haemophilia tecentriq oncology actemraroactemra immunology xolair immunology herceptin oncology avastin oncology kadcyla oncology mabtherarituxan oncologyimmunologyreporting strategy roche reporting strategy roche committed transparent reporting endeavour drive economic social environmental performance diligence financial performance sustainability built business strategy part everyones job roche focus finding new medicines diagnostics establishing databased insights evolve practice medicine help patients live longer better lives reporting approach roche committed transparent reporting reviewed externally appropriate endeavour drive economic social risk management embedded levels environmental performance diligence roche group pharmaceuticals diagnostics financial performance divisions global functions conduct formal risk opportunity assessment least reporting scope boundaries year must develop response plans financial nonfinancial reporting consists material risks opportunities annual report finance report online report contains annual financial read corporate governance statements consolidated financial statements nonfinancial performance indicators covers also identify longterm business sustainability regions divisions roche group trends associated risks opportunities january december financial annual basis integrate existing reporting scope defined outlined group risk management process year ten finance report significant emerging trends including associated risks changes scope compared opportunities identified internal external sources gri standards materiality member global reporting based findings sustainability steering initiative gri community since committee prioritises selects top business followed gri g guidelines since sustainability trends two important transitioned reporting reference business sustainability trends gri standards using gri standards following future work ii mistrust disclose critical impacts activities scepticism science two trends well environment society economy one associated opportunities risks described risk management risk management policy sets roches un sustainable development goals approach identifying analysing managing support united nations sustainable reporting internal external risks development goals sdgs within sphere opportunities consolidated group risk report corporate business strategy contribute covers material risks opportunities number sdgs greatest contribution discussed annually corporate executive sdg good health wellbeing goal committee reviewed board directors closely connected achievement universal health coverage goes hand hand effectiveness group risk management better access quality essential medicines process regularly monitored group risk diagnostics fully aligned vision advisory team overall process reviewed improve save lives since sdgs audit committee board directors integral part annual reporting report arrochecom rochecomarepdf rochecomfbepdf risk management rochecomriskmanagement key performance indicators rochecomperformanceour reporting approach roche business sustainability trends examples contribution un goals listed un sdg webpage see link future work mapped material topics trend descriptor new diverse complex working models remote featured signatory un hybrid lead increasingly fluid workspace workforce global compact ungc commit integrate requires agile workforce management avoid negative impacts universal principles areas human well leverage positive impacts talent attraction retention rights labour environment anticorruption engagement especially highly innovationdependent sector business strategy culture daily operations report results achieved opportunity roche positioned attractive employer year published first communication flexible ways working progress cop first quarter submit second cop first quarter risk disconnection within company increased silo thinking reduce innovation drive duplication external assurance selected key figures nonfinancial mistrust scepticism science reporting year ended december trend descriptor growing educational gap populism subject limited assurance procedures increasing spread fake news intended unintended leading performed pricewaterhousecoopers ag pwc mistrust scepticism science medical therapies pharmaceutical independent thirdparty assurance provider industry institutions pwc provides limited assurance selected key figures areas safety security health opportunity competitive advantage created roche environmental protection ii people culture strengthening relationships governments patient iii grants donations sponsorships key organisations payers doctors eg sharing information providing figures disclosed annual report andor education nonfinancial reporting webpage together related pwc limited assurance report risk patients society benefitting scientific defined nonfinancial reporting metrics advancements resulting medicines due lack awareness guidelines basis preparation saturation false information see independent assurance report full list business sustainability trends associated risks opportunities found risk management website link previous materiality impact purpose patients need next environment identify meet needs respect healthy planet every day must sustainable succeed environment always priority sustainability built business founding families company strategy part everyones job roche committed halving environmental impact operations products approach holistic integrates three aim reduce greenhouse dimensions sustainability gas emissions absolute zero society contribute better partnering suppliers reduce tomorrow emissions mutual benefit environment minimise impact nature economy economy invest medical advances business must meet needs patients create jobs ensure livelihoods continue creating quality jobs provide people families secure livelihoods mean us roche earning competitive returns investors every day promoting innovation translating science pioneering medicines society diagnostics help patients live longer contribute better society enabling better productive lives enabling right treatment right patient right support contribute time right value developing local economies new medicines ways diagnosing disease gaining insights data commitment described strategy setup expand access innovations help designed innovation autonomous research patients live longer better lives comes development centres alliances deep respect human rights everyone external partners foster diversity reach especially patients business partners scientific approaches agility roche suppliers local communities course operates countries local colleagues around world emphasise teams implement strategy measure employee safety health development performance report stakeholders promoting diversity inclusion integrity mutual progress towards goals set respect equal opportunities sustainability rochecomsustainability materiality rochecommateriality stakeholder engagement rochecomstakeholderengagement key performance indicators rochecomperformance contribution un sdgs rochecomunsdgsmateriality impact roche society environment sustainability economy material topics access healthcare ethics compliance affordability healthcare compliance availability healthcare ethics transparency sustainable healthcare systems human rights digitalisation employee engagement cybersecurity organisational agility data privacy preparedness ageing society personalised healthcare talent attraction retention realworld data energy efficiency science innovation energy efficiency patient centricity preparedness ageing society longterm mindset rd efficiency longterm mindset product quality safety product safety product quality materiality assessment impactdriven sustainability initiatives stakeholder engagement order maximise impact within engaging stakeholders essential build beyond healthcare industry joined trust understanding expectations two notable sustainability initiatives namely embedding feedback strategy sustainable market initiative value daily business able jointly address balancing alliance common issues develop longterm solutions sustainable market initiative smi order identify topics particularly multistakeholder initiative aims lead relevant roche stakeholders society transition sustainable future convening large deliver lasting shared value public privatesector leaders align conducted indepth materiality assessment economic value social environmental corporate level among key stakeholders sustainability part smi commitments approach materiality climate actions line science assessment integrated building group based targets initiative sbti value risk management process inclusive balancing alliance vba initiative designed collaboratively colleagues across alliance multinational corporations multiple functions gathered insights develop pilot alongside leading academic broad range internal external stakeholders institutions standardised methodology identify important pressing issues ensure greater sustainability transparency roche address next three five years done greater disclosure identified material topics clustered eight environmental social economic impact main categories stood highly relevant also support makeitmandatory campaign us key stakeholders properly address calling mandatory requirements topics aligned large businesses financial institutions current goals measuring performance assess disclose impacts defined set indicators additionally dependencies biodiversity currently conducting indepth materiality assessment group level order update list material topics identified materiality impact roche impact impact performance material topics supporting un sdgs society million patients treated roche medicines access healthcare contribute billion tests conducted roche product quality better tomorrow diagnostics products safety new molecular entities clinical development digitalisation women executive positions science innovation ethics compliance employee engagement environment decrease environmental impact energy efficiency per employee since minimise impact nature electricity coming sustainable sources decrease greenhouse gas emissions since economy sales invested rd longterm mindset invest medical employees advances create jobs ensure livelihoods clustered material topics details see rochecommateriality strategy focus finding new medicines diagnostics many different stakeholders healthcare establishing databased insights evolve ecosystem broaden access offerings practice medicine help patients live people need ultimately longer better lives provide seamless patient journey continue concentrate energies business environment undergoing prescription medicines vitro diagnostics tremendous change facing new challenges increasingly data insights rather due complexity care increasing diversify sectors like generics pressure healthcare budgets biosimilars overthecounter medicines time see new opportunities arising major advances life sciences digitalisation delivery create value healthcare stakeholders partner choice bringing significant medical benefit patients doctors turbulent times guided payers offering great place work common purpose patients employees delivering sustainable positive need next company bringing contribution society earning competitive novel diagnostics treatments patients returns investors years patients remain core reason come work every day ultimately delivering commitments takes people integrity courage passion making difference patients people focus vision fitting treatments proud say roche patients providing right therapy right patient ensure best response right leadership inspires outcomes matter time right value approach combines embracing diversity inclusion different rich expertise pharmaceuticals diagnostics backgrounds perspectives experiences expanded data science capabilities drive across entire organisation foster innovative effective efficient research solutions benefit patients ways enable better therapeutic decisions patients working enable agile networked responses everincreasing pace change balancing pursuit excellence science rests four needs stability speed flexibility key elements exceptionally broad deep understanding disease biology seamless setup designed innovation integration capabilities pharmaceuticals autonomous research development centres diagnostics diversity approaches alliances external partners maximise innovation longterm orientation foster diversity scientific approaches agility global geographical scale reach working partnership third parties enables us attract talent leading global offer integrated solutions improved medical science clusters quickly bring solutions health economic benefits work people need themour strategy roche focus leadership fitting treatments patients inspiring outcomes matter distinctiveness ways working excellence science agile networked delivery setup value stakeholders built innovationdiagnostics committed advancing diagnostic solutions support healthcare professionals making critical decisions patients health also improving way essential tools integrated health systems around worldhiro nitta senior scientific fellow tucson usa hiros work roche enables follow passion developing diagnostics address unmet patient needs many scientific breakthroughs already impacted lives millions patients around worlddiagnostics roche dr bushra jamil professor medicine infectious diseases karachi pakistan dr jamil partners stakeholders across healthcare system increase access care diagnostics pakistan efforts led provision patientcentric integrated care hiro nittadiagnostics roche steadfast commitment improving access vital diagnostics hiro nittas dedication continually improve accurately diagnose herpositive patients access patients began anywhere world succeeded teenager yearold college student japan hiro developed passion aspects beginning histology study tissues spent days new diagnostic launched hiros dissecting samples analysing data eventually commitment deepened missing one patient publishing findings serve could receiving lifesaving therapy one foundation scientists involved developing many hiro says new goal develop stateoftheart tissuebased diagnostics even precise diagnostics early academic days beginning hiros work roche enabled follow hiros decadeslong commitment developing passion developing diagnostics address unmet even precise diagnostics herpositive patient needs created nextgeneration breast cancer patients journey hiro considers test determine specific type lifes work hiro began working cells present tumour valuable insight ventana medical systems acquired used inform new therapy protocols could roche today senior scientific eventually enable herpositive patients fellow clinical development medical affairs experience better outcomes roche diagnostics solutions campus tucson arizona plans slowing hiro also discovered previously unknown type time soon hiro explains tumour cell structure working much patients theres time breast cancer researchers investigate waste type tumour responds targeted therapy time developing tests many million cases breast provide valuable information cancer diagnosed globally year fuelled obtained diagnostics currently gene many herpositive patients available hiros research novel benefit specific targeted therapy assay evaluates gene determining patients receive protein single tissue sample treatments initially required highly specialised presented meetings united states technology women didnt get right canadian academy pathology well treatment challenges testing european society medical oncology hiro says wasnt okay access multiple elements working ventana hiro dedicated hiro improving access means cancer developing simpler test could patients opportunity tested conducted lab could quickly innovative accurate methods breast cancer fact sheet world health organization recommendations human epidermal growth factor receptor testing breast cancer american society clinical oncologycollege american pathologists clinical practice guideline update journal clinical oncology everyone deserves access best cancer diagnostic tools therapies time people love results used select point expected survive considers treatment protocol effectively eventual recovery invaluable second save extend lives hiro describes chance continue work even commitment way patients hiro explains impact experience shouldnt matter someone lives much money everyone deserves understand ever fear hope access best cancer diagnostic tools patients feel worry limited treatment therapies time options got second chance live believe people love help make goal reality survived could work harder ever give continue working developing better cancer patients second chance precise tissuebased cancer diagnostics experience left drives long make greater difference inspiration everywhere hiro still needs manage life due symptoms hiros accomplishments begin long covid reminds laboratory knows impact work need better testing treatment choices happens outside doors hiro found patients cancer treatment facilities around world meeting research collaborators visits life full provide invaluable opportunity connect committed hiro work cancer patients family members interests outside lab awardwinning even casual conversation lobby magician performs children hospital hospital helps hiro maintain focus paediatric units also raises standard poodles ultimate beneficiaries work shows competition add love disney talent baking hiro looks getting know patients people definition wellrounded individual better understand individual journeys passionfilled life challenges face hopes future focus patients hiro explains hiros many scientific breakthroughs already know must impacted lives millions patients around world commitment reaching even hiro another unique perspective inspires people highly precise diagnostics work march experienced lead effective treatments continues dangerously severe covid infection one drive every daydiagnostics roche quest continuously improve breast cancer diagnosis hiro nitta spends days investigating cancer cells dedicated ensuring patients access appropriate treatment options improved understanding cancer biology enabling access quality care critical diagnostics pakistan growing father physician dr bushra move towards patientcentred care jamil exposed practice medicine lack patientcentred system also young age reading medical books child significant challenge dr jamil sees critical instilled love science drive follow gap patient requires number different fathers footsteps despite female tests often sent different clinics predominantly maledominated field dr jamil different areas rather basic diagnostics studied various areas medicine pakistan available one roof incredibly united kingdom professor inconvenient patients something medicine infectious diseases aga khan need address university hospital aku karachi pakistan also president medical microbiology dr jamil served national coordinator infectious diseases society pakistan mmidsp global fund fight aids tuberculosis malaria grants ministry health diagnostics infrastructure key islamabad procured covid mitigation great deal dr jamils work aku grant focus strengthening health systems mmidsp focused increasing access quality ensuring provision integrated care healthcare pakistan lack effective critical diagnostics one roof healthcare delivery system huge challenge type clinical service needed across pakistan says dr jamil although varies country says dr jamil covid province province system extremely served catalyst funding fragmented poor quality urgent ability diagnose infectious diseases need invest close gaps particularly using equipment model relates accessing diagnostics services truly move needle comes adequately training healthcare professionals patient care unfortunately covid pandemic exacerbated roche working dr jamil ensure issues brought realisation district level secondary care hospitals robust diagnostics infrastructure covid equipped diagnostics systems needed infectious diseases absolutely provide onestopshop approach essential diseases diagnosed right equipment need use early stage patients eventually effective efficient way possible says dr jamil diagnosed always defined path huge impact case detection take especially live rural area well followup treatment mention patients go private clinic fact done easily conveniently need urgent treatment patient greatly benefitdiagnostics roche dr bushra jamil infectious disease expert dr jamil knows important role diagnostics play detection treatment diseases tuberculosis hiv malaria critical diagnostics infrastructures place dramatically change quality timeliness care patients receivediagnostics roche need able bring diagnostics available affordable simple fast public healthcare system economical manner education key medical education opportunities healthcare another important component increasing professionals execute disease awareness quality care patients pakistan properly education campaigns emphasise significance training healthcare professionals principles timely diagnosis treatment prevention effective diagnostics management management across variety disease areas diseases workforce inadequately trained tend bypass essential steps patients look future treated based previous experience rather asked future could look like accurate diagnostics says dr jamil healthcare pakistan dr jamils answer harmful patient treatment clear publicprivate partnerships critical based accurate timely diagnostics need able bring diagnostics also negative implications community available affordable simple fast country whole public healthcare system economical manner work together train workforce roche diagnostics pakistan partnered build diagnostics capabilities dr jamil mmidsp increase advocacy procedures improved patient journeys around diagnostics enable improved patient confident implementing changes access order minimise countrys disease truly make difference lives people impact partnership deliver continuing pakistan integrated solutions improve outcomes diagnostics division marked digital pathology portfolio three key trends first global awareness transforming pathology ventana dp value diagnostics across every aspect highcapacity slide scanner creates highresolution healthcare grew significantly covid digital images stained tissue samples help portfolio continued expand meet demands diagnose cancer determine patients related diseases evolution second treatment digital pathology open environment also saw measurable growth base business allows software developers easily integrate tests cancer cardiovascular disease image analysis tools tumour tissue infectious diseases third advanced upath enterprise software efforts build sustainable digital health business set us success open digital ecosystems connect innovators digitalised market startups technology leaders give lab professionals clinicians researchers preventative screening followup care patients faster access wider range diagnostics play increasingly critical role across innovation advances personalised entire patient journey early diagnosis healthcare solutions time thousands disease progression may slowed even stopped data points patients create throughout diagnostic testing provide patients families journey help identify changes health healthcare professionals information may enable tracking similar patient groups across lead best possible outcome healthcare institutions geographies artificial systems access diagnostic information intelligence ai machine learning managing diseases helps avoid unnecessary service eventually allow comparison outcomes delivery reduces overall cost care improves well predictive measures effectiveness importantly contributes saving lives moreover carefully assessing diversity patient populations diagnostics clinical demonstrated covid pandemic trials demonstrating commitment developing diagnostics information solutions make solutions help improve outcomes patients major difference countrys ability cope around world example diagnostics infectious disease outbreaks maintain health division contributing meaningful way systems advanced diagnostic solutions support rochewide africa genomics program agp earlier decisionmaking help reduce hospitalisation enable targeted treatment strategies improve diabetes care advancing integrated patient management personalised diabetes management ipdm strategy successfully deployed customer driving innovation digitalisation population insights dashboard streamline building divisionwide digital data management process enable healthcare foundation strategy portfolio professionals administrators payers view advancing ambition establish sustainable population level trends time th digital health business unified anniversary mysugr patientcentric interface digital health portfolio navify core open ecosystem introduced brand providing range nextgeneration extended functionalities expanded smartphone software solutions compatibility mysugr pump controldiagnostics roche tests conducted roche diagnostics products billion cobas systems installed since inception active inlicensing agreements active outlicensing agreements diagnostics facts covid tests enabled per month million covid key launches name launch date approval indicationdisease etc systemplatform covid variant tests march research use sarscov b variant omicron subvariants cobas ba ba ba ba ba delta lightcycler cobas z depending test cobas sarscov duo test june fda emergency sarscov rna nasal nasopharyngeal cobas use authorization swab specimens elecsys igra sarscov test august ce mark supports understanding immune response cobas e e sarscov infection vaccination e e analysers sarscov rapid antigen test october ce mark sarscov tests delivering reliable results instrument needed minutes sarscov rapid antigen test nasal sarscov antigen self test nasal cobas sarscov qualitative test october fda covid pcr test performed cobas highthroughput platform new platforms tests digital solutions pathology lab roche information solutions new platform new digital solutions new tests new digital solutions diagnostics point care key launches molecular lab new test new platforms new tests diabetes care core lab new digital solution new platforms new tests new digital solution cancer key launches name launch date approval indicationdisease etc systemplatform cobas hpv test june ce mark selfsampling human papillomavirus hpv screening cobas molecular selfs ampling solution prevent cervical cancer instruments ventana dp june ce mark creates highresolution digital images stained tissue slide scanner part samples help diagnose cancer digital pathology portfolio benchmark ultra plus june ce mark global fully automated tissuestaining process new system ventana mmr rxdx panel august fda label companion diagnostic solid tumours treated benchmark ultra expansion mercks immunotherapy keytruda digital lightcycler system august countries worldwide nextgeneration digital pcr system help clinical new system cemarked fda researchers better understand nature patients k exempt status cancer genetic disease infection pathway antiher october fda companion diagnostic assessment benchmark ultra ihcish b test low status metastatic breast cancer patients slidestaining instrument prame epr antibody october na evaluates prame protein expression patients benchmark ultra ihcish suspected melanoma instruments ventana folr folr november fda first immunohistochemistry companion diagnostic aid benchmark ultra rxdx assay identifying epithelial ovarian cancer patients eligible targeted treatment elahere immunogendiagnostics roche key launches name launch date approval indicationdisease etc systemplatform cobas infinity edge january rolling launches cloudbased platform connecting patient test results three modules unite selected markets medical records thirdparty applications scribe smart cobas pulse january ce mark blood glucose management solution mobile handheld blood glucose digital health capabilities management device floodlight january mdr certification smartphone app enables datadriven smartphone decisionmaking patients multiple sclerosis mysugr pump control april launched allows diabetes patients import temporary basal accuchek insight selected markets rates accuchek insight insulin pump insulin pump mysugr app three lightmix modular virus may available research mpox virus detection lightcycler ii kits quantitative pcr tests use majority instrument countries worldwide cobas z analyzer elecsys hcv duo immunoassay july ce mark simultaneous independent determination cobas e cobas hepatitis c virus antigen antibody status e immunoassay single human plasma serum sample analysers elecsys amyloid plasma panel july fda breakthrough device detects measures alzheimers disease biomarkers elecsys technology designation blood plasma cobas pure integrated solutions september fda next generation innovation cobas family cobas pure serum work area solutions cobas mpxv november fda emergency pcr test qualitative detection dna cobas use authorization mpox virus elecsys ad csf assays december fda cerebrospinal fluid assays supporting accurate cobas fully automated timely diagnosis immunoassay analyserspharmaceuticals proof scientific innovation leads products truly save improve patients lives focusing oncology immunology ophthalmology infectious diseases neuroscience metabolic rare diseases translate excellence science effective medicines patientsfrankline akinyi otieno breast cancer patient kenya east africa frankline received treatment breast cancer first national access programme kenya programme important step kenyan women breast cancer access standardofcare treatmentpharmaceuticals roche ricky alas global value stream strategy lead basel switzerland ricky part team working improve patients receive healthcare access medicine work resulted new transformative way provide direct topatient treatment delivery home care services frankline akinyi otienopharmaceuticals roche overcoming challenges accessing breast cancer treatment kenya peer educator centre health wellbeing also faced stigma solutions facility ukwala town kenya frankline family friends colleagues amplified akinyi otieno works women educate concerns told cancer expensive support range health issues people dont survive chemotherapy past six years visiting women community speak reproductive family difficult time accepting sexual health including topics sexually cancer diagnosis also concerned transmitted infections family planning frankline medical treatment insisting also educates women perform breast first try herbal medicine although frankline selfexaminations encourages go reservations tried option two months cervical cancer screenings ultimately herbal medicine didnt work frankline returned jootrh proceed role requires extensive knowledge recommended treatment plan doctors topics frankline already learned long ago importance selfexaminations confronted access challenges screening observing posters hospital frankline underwent mastectomy followed used visit frequently asthma eight cycles chemotherapy impact routinely performing breast selfexaminations life indeed significant easy proved critically important practice journey says never surgery life found lump really wasnt comfortable got quite sick chemotherapy arm became frankline immediately consulted doctor constrained surgery couldnt lift heavy referred specialist jaramogi oginga objects hang clothes dry line sleep odinga teaching referral hospital jootrh right side people started seeing differently investigation following ultrasound selfesteem suffered result mammogram biopsy may frankline told breast cancer following surgery chemotherapy frankline continue hormonal exploring alternative treatment options treatment treatments covered huge shock hearing breast national health insurance fund nhif cancer recalls really wasnt expecting point faced difficult breastfeeding time prior decision nhif covered mastectomy tests done indicated lump chemotherapy well first four hormonal normal told would subside time treatments needed pay remaining treatments frankline explains upon hearing diagnosis frankline hesitant couldnt afford didnt know follow recommended hospital treatment next stuck stop treatment afraid potential effects two months weighed options want advocate women get screened earlier better get right diagnosis treatment soon frankline answer june bright future ministry health kenya nhif roche frankline thankful able announced partnership make breast cancer access treatment also recognises treatment available nhif members kenya importance knowledge impact first national access programme screening selfexamination saved life cancer medicines kenya important step says want advocate women get ease financial burden kenyan women screened earlier better get breast cancer ensure access right diagnosis treatment cancer doesnt standardofcare treatment death sentence long get diagnosis early enough breast cancer commonly diagnosed cancer kenya cases diagnosed today frankline responding well year breast cancerrelated treatment optimistic deaths partnership roche future holds believe dreams helping strengthen diagnostic ecosystem future go planned live breast cancer screening early diagnosis normal life says patients well improve referral pathways treatment centres women get big part future helping son treatment need timely manner realise dreams son comfort sick tells well frankline welcome news meant want best says frankline worry paying pocket wants pilot grows could continue treatment hope help education know made easier could live see happen fly get full treatment covered around world cancer global stage incidence cancerrelated mortality kenya world health organization region africa asco postpharmaceuticals roche like many women breast cancer kenya frankline faced financial challenges prevented getting medicine needed new collaboration ministry health kenya nhif roche made breast cancer treatment available making easier accessible women like frankline receive standardofcare treatment frankline well looks forward bright future son improving access treatment patients comfort home ricky alas worked consultant digital delivery specialty medicine still uncommon innovation corporate venture building yet make significant improvement san francisco exposed number patients quality life also industries ranging financial services potential save healthcare costs consumer packaged goods ten years efficient processes delivery treatment ricky ready change industries hed worked drawn healthcare ricky global idp team initially wanted part organisation tasked finding way make home delivery direct tangible impact improving peoples evrysdi oral treatment spinal muscular lives joined genentech digital atrophy sma reality small feat considering transformation lead global supply chain nothing like existed medicine would typically picked specialty shortly settling ricky given treatment centre could hours opportunity work project called integrated patients home set create solution direct delivery patients idp desirable patients ecosystem value patients clear idp stemmed feasible viable according ricky felt exercise answer question would almost like startup times healthcare system look like designed get build new business established around patients family members company roche give us opportunity needed wanted could make amazing life think roches ambition provide initial thinking improve benefit patients less cost society idp processes healthcare delivery better support exactly says ricky im proud work patients caregivers simplify organisation ambitious goals get treatments key solution pointed direct also comes new creative ideas topatient delivery home care services achieve dont always know work thus idp born successful project always trying find ways improve would improve quality healthcare service peoples lives patients family members alleviate hospital clinic burden reducing number inperson programme launched patient visits improve outcomes patients interest offices around world participate greater convenience potentially better overwhelmingly positive however road treatment adherence ahead challenging team forged new paths every direction legal regulatory meeting patients requirements supply logistics solutions home delivery consumer goods pizza also taking account stakeholder needs appliances part everyday life home preferences unknown andpharmaceuticals roche ricky alas ricky idp team work colleagues around globe design develop implement tailored programmes enable delivery treatments directly patients homes convenient solution save countless hours travel time specialty hospitals patients rare chronic conditions like sma haemophilia caregivers lifechangingpharmaceuticals roche believe evolution healthcare going continue towards much patientcentric realm unconstrained space recalls ricky significant impact improving patients road map industry barometer success lives ricky enjoys project figuring went hit relationships hes formed feel like ive roadblocks amplified genuinely made friends even though ive met look despite challenges person think comes idp seen significant growth increasing getting meaningful work cool way initial launch nine pilot programmes dedicated people first year programmes roche affiliates across globe trailblazing new paths access idp shows sign slowing made idp successful people affiliates continue joining project creating ricky says without hesitation lead fitforpurpose directtopatient project respective countries outofhospital solutions fact ricky hopeful involved daytoday work overcame could serve future capability constraints every step way project several roches pipeline products dont wouldnt possible without passion initiative see world talk idp drive towards single goal addressing project much longer way unmet needs patients demonstrating full value medicines patients ecosystems collaboration without borders local teams came together design ricky thinks roche play role helping deploy solutions collaboration ecosystem ecosystems adapt establish necessary partners power resources full capabilities enhance access firmly place idp network behind ricky feels fortunate patients heart believe gets work colleagues almost every evolution healthcare going continue towards country diverse perspectives much patientcentric realm says idp crossfunctional backgrounds every level beginning theres much project working together trying help trigger transformation find solutions challenges explains recently relocated basel wife two young children ricky excited continue clear ricky passionate playing part idp excited meet making difference people idp friends hes made along way clear commitment innovation commitment innovation never clinical decline people early alzheimers clearer past year made major disease roche remains committed disease investments research development one complex neurological disorders unique combination autonomous major public health challenges independent research organisations together continuing develop deliver tests enable investment strong network early accurate diagnosis pipeline external partner organisations globally investigational medicines different targets drives pioneering scientific technological types stages disease breakthroughs across healthcare power partnerships launched vabysmo first bispecific facilitating patient access quality medicines antibody approved eye targets heart business meet rising global inhibits two signalling pathways linked demand highquality accessible healthcare number visionthreatening retinal conditions services integrated comprehensive neutralising angiopoietin ang vascular actionable plans work enhanced endothelial growth factora vegfa vabysmo patient partnerships worldwide approved countries around world including united states japan entered first partnership united kingdom european union holistic approach improving population health people living neovascular wet agerelated international federation red cross macular degeneration diabetic macular red crescent societies ifrc collaboration oedema review regulatory authorities help us unlock access previously underserved ongoing continue pioneer new ways populations worldwide strengthen treat visionthreatening eye diseases commitment meet needs patients matter live european commission approved polivy combination previously untreated diffuse large advancing inclusive research bcell lymphoma dlbcl firstinclass deeply committed addressing barriers bispecific antibody lunsumio treatment clinical trial participation advancing inclusive relapsed refractory follicular lymphoma research believe improving health outcomes lunsumio represents new type immunotherapy patients core mission chemotherapyfree fixedduration committed industry leaders offering treatment option potential provide patients serious lifethreatening diseases durable remissions offer significant period chance receive investigational medicines time without treatment following initial therapy polivy combination first treatment option aiming continuously evolve processes years show clinically meaningful improve accessibility convenience ultimately improvement progressionfree survival adherence leading better outcomes patients approved eu patients previously reduced burden caregivers order untreated dlbcl meet unique requirements country global country colleagues working closely although phase iii graduate ii trials together external stakeholders go extra meet primary endpoints slowing mile patientspharmaceuticals roche pharmaceuticals clinical pipeline phase phase ii phase iii registration oncology inflammationimmunology neuroscience infectious diseases ophthalmology metabolics others pipeline new molecular entities covers broad range diseases highly innovative technologies applied create produce active molecules new partnerships product outlicensing agreements divestments acquisition phc agreements product technology discovery number new licence agreements partnerships research discovery collaborations agreements derived existing alliances pharmaceuticals roche major approvals china europe ctemraroactemra l unsumio rheumatoid arthritis subcutaneous follicular lymphoma thirdline treatment rozlytrek polivy ntrkpositive solid tumours diffuse large bcell lymphoma firstline treatment rozlytrek major approvals rospositive nonsmall cell lung cancer tecentriq nonsmall cell lung cancer adjuvant therapy tecentriq nonsmall cell lung cancer adjuvant therapy v abysmo diabetic macular oedema v abysmo neovascular wet agerelated macular japan chugai degeneration us ctemraroactemra covid pneumonia ctemraroactemra g azyvagazyvaro covid pneumonia chronic lymphocytic leukaemia firstline treatment ctemraroactemra h emlibra giant cell arteritis intravenous acquired haemophilia c otellic perjeta herceptin histiocytosis herpositive colorectal cancer l unsumio p olivy follicular lymphoma thirdline treatment diffuse large bcell lymphoma firstline treatment tecentriq tecentriq alveolar soft part sarcoma nonsmall cell lung cancer adjuvant therapy evrysdi abtherarituxan spinal muscular atrophy presymptomatic paediatric months neuromyelitis optica spectrum disorder v abysmo v abysmo diabetic macular oedema diabetic macular oedema v abysmo v abysmo neovascular wet agerelated macular degeneration neovascular wet agerelated macular degeneration xofluza influenza paediatric oncologyhaematology inflammationimmunology neuroscience infectious diseases ophthalmologypersonalised healthcare years helped lay scientific groundwork personalised healthcare treatments target underlying biology cancer diseases working taking personalised healthcare toward future care tailored individuals needs unique genetic profile un sdgs material topics patient centricity rd efficiency personalised healthcare realworld data preparedness ageing societysusanne frstmichna cancer unknown primary cup patient sinntal germany susanne diagnosed cancer unknown primary cup early opportunity receive tailored treatment plan informed comprehensive genomic profiling cgppersonalised healthcare roche dr konstantinos balaskas medical ophthalmologist london united kingdom dr balaskas team moorfields eye hospital utilising remote vision monitoring patients retinal disease ambition empowering assume greater ownership management health susanne frstmichnapersonalised healthcare roche comprehensive genomic profiling brings new hope fight rare cancers march driving home example lungs breast therefore job frankfurt germany susanne frstmichna patients cup treated standard casually touched neck found several chemotherapy unfortunately prognosis poor lumps one side returned home median survival following diagnosis evening contacted physician friends months recommended consult specialists thus began journey never imagined susanne concerned next steps since would face many unknowns could think going deal unfortunately number visits different specialists happening height susanne told something wrong covid pandemic susanne often kidney function subsequent ct scan alone attending appointments clinic near revealed large number swollen lymph nodes home hard husband suspected lymphoma always support allowed pick remember day scan sons afterwards susanne recalls final th birthday susanne recalls day consultation doctor allowed celebrating took turn asked options worst urologist called moving forward moment evening made anxious next day never forget family doctor told cancer needless say stunned path forward susannes doctor recommended move elusive diagnosis care specialists heidelberg testing lymph nodes drove heidelberg heavy hearts results reveal cancer originated returned completely different people asked meant oncologist said says got car headed home cancer unknown primary cup says confidence restored susanne soon got home started researching online like everyone days appointment susanne told learned scary type cancer option potentially receiving original tumour found personalised treatment plan using technology doctors able find secondary tumours analyses dna patients metastases spread result primary one technology called comprehensive genomic profiling cgp way finding unique cancer diagnoses cup fingerprint cancer tumour help absence primary tumour causes practical determine specific genomic alterations problems traditional treatment approaches targeted molecularly guided rely knowing site cancers origin therapy cancer immunotherapy approach understanding cancers secret syndrome new scientist genomic testing foundation medicine inc call yet changed everything doctor said targeted drugs treat specific alteration wed able get control represents shift treating cancer based dedicated plus husband site likely site origin treating patient time together talk laugh think like susanne based clinically relevant future susanne says throughout susanne genomic changes suspected driving cancers able continue working growth providing complete picture husband found new passion mountain susannes cancer cgp could help inform biking around scenic roads near home tailored treatment plan potentially remove take different route every day end need determine cancers original location places around weve never body team doctors described wonderful says excitement opportunity knew seize voice opportunity recalls susanne positive outlook personalised treatment plan susanne feels incredibly lucky susanne underwent cgp tests evaluated opportunity receive personalised treatment genes known associated cancer growth plan informed cgp impact cgp answers would provide essential first steps constantly evolving diagnostics tools developing informed treatment strategies solutions improve targeted therapies august susanne thrilled developed data generated told cgp revealed genomic alteration improve understanding cancer biology driving cancers growth call susanne husband along son yet changed everything cup doctors daughter already planning holidays said targeted drugs treat together united states spend time specific alteration wed able get travelling enjoying others company control best gift anybody im living life like always used travel could given point says susanne closeknit family didnt really allow anything change life negative soon susannes cancer alteration things course deal illness identified personalised treatments began thinking positively always one travels heidelberg every four weeks basic principles says susanne ive given receive therapy clinic grateful gift seeing kids grow adulthood husbands company car ride still spend time husband time team wonderful continue enjoy lifepersonalised healthcare roche first diagnosed cancer unknown primary susanne unsure future would hold utilising comprehensive genomic profiling determine personalised treatment plan hopeful future family continue enjoy time together exploring scenic landscape near home sinntal germany digital health solutions transforming care living progressive eye diseases ophthalmologist dr konstantinos balaskas urgent need remote vision monitoring firm believer old adage eyes conjunction regular office visits quickly windows soul interest ocular resulted moorfields roche partnering medicine began medical studies pilot programme address problem athens greece led current role retinal specialist principal investigator collaboration roche began research artificial intelligence digital necessity within four weeks deployed technologies moorfields eye hospital programme continuing develop london united kingdom part offering moorfields medical retina clinics says dr balaskas dr balaskas credits keen interest field ophthalmology fact constantly proposed solution app called home evolving ive always liked ophthalmology vision monitor patients chronic eye instinctively dramatic rapid technology disease could download smartphone transformation revolutionised way tablet monitor vision comfort provide care patients says year home patients used app year area constantly reinventing perform visual function tests test results able treat diseases eye instantly available clinicians view used incurable change patients test results practitioners notified could follow goal prevent vision loss especially patient directly retinal disease says dr balaskas long ago diagnosis chronic retinal disease would registered approximately patients devastating patient absence home monitoring service ambition effective treatments recently also empowering assume greater ownership hoping improve quality life patients management health reflects dr balaskas using digital technologies may give greater access care future potentially allowing changing landscape care monitored away hospital could assumed type remote closer home monitoring would create greater distance clinicians patients dr balaskas urgent need rapid solution says opposite true fact data generated april early stages covid home vision monitor help inform pandemic dr balaskas colleagues knew enrich discussions physician needed urgent solution many patients patient experience greatly impacted retinal disease fall highrisk population relationship patients positive developing serious illness due covid way actually brought us closer avoiding hospital attendances infused sense reassurance theyre beingpersonalised healthcare roche dr konstantinos balaskas thanks technological advancements treatment retinal diseases hoped quality life patients improved potential allowing monitored away hospital closer homepersonalised healthcare roche hope programme enables us provide care right patients right place right time monitored regularly says patients also still medical association possibility maintain regular appointments scaled instigated discussions around potential home vision monitoring future conjunction regular office visits remote roche team planning limited monitoring programme potential reduce product release united states expanding burden hospital visits patients also pilot uk healthcare system hope programme enables us provide care dr balaskas possibilities technology right patients right place right along others artificial intelligence time says dr balaskas chronic retinal disease decision support systems telemedicine better prognosis earlier diagnosed virtual clinics really way future treatment started longterm benefits aspiration hope able healthcare system delivery integrated approach innovative sustainable care home vision monitor solutions integration key materialising currently aid diagnosis retinal disease benefits technologies says help identify changes vision time putting together enable better used aid physicians clinical access quality care patients future decisionmaking meantime dr balaskas team learning future celebrating recent win health first initiative kind service journals patient safety awards home ophthalmology attracted significant vision monitor app awarded best virtual amount attention amongst international remote care initiative great retinal community learnings barriers moment true testament innovation enablers deploying home vision monitoring collaboration patientcentric approach recently published journal american dr balaskas says proudly tailoring care personal todays convergence pioneering science delivery enables longterm access advanced technologies data analytics sustainability resiliency shifting healthcare onesizefitsall approach delivery patientcentred aim catalyst contributor care tailored care solutions commonly holistic thinking crosssector collaboration call personalised healthcare enabling collective effort necessary turn personalised roche truly integrate holistic care experience care reality people societies spans prevention detection diagnosis treatment ongoing monitoring care partnering across healthcare ecosystem individual people essential designing testing implementing new personalised solutions improve health insights personalised care individuals enable healthcare professionals highquality data analytics engines make confident healthcare decisions drive personalised healthcare today reducing cost burden society today healthcare systems produce wealth untapped roches partnering efforts span pharma information fed diverse health data biotech companies startups nongovernmental individuals generate throughout lives organisations healthcare providers governments data yield valuable insights allowing regulatory authorities patient communities early prevention identifying patterns trends academia technology companies population health managing disease personalised way finding tumours fingerprint cancer disease genome driven roches wide range diagnostic information genomic alterations comprehensive genomic solutions generate manage billions data profiling cgp type cancer genomic testing points year contain highquality helps find unique fingerprint information potential trigger patients cancer tumour help determine advances personalised healthcare taken behaves grows together contribute significantly longitudinal data provide comprehensive picture together roche foundation medicine patients help support healthcare professionals working advance cancer care research decisionmaking clinical decision embedding cgp throughout care continuum support tools point care cgp inform easier faster better clinical decisions cgp also drives partnerships collaborations faster efficient rd insights personalised healthcare aims transform generated helping optimise clinical trial design care seamless individualised experience supporting development effective patients also need transform care targeted treatmentspersonalised healthcare roche flatironauthored publications twentythree flatironauthored papers accepted published peerreviewed patient profiles journals linked patient profiles foundation medicine flatiron health clinicogenomic database cgdb new molecular profiling flatiron health new molecular profiling integration milestones caris life sciences foundation medicine international expansion flatironauthored poster discussions international expansion focused transforming global oncology research care subsidiaries fourteen accepted flatironauthored poster japan germany united kingdom discussions presentations showcasing flatirons scientific leadership key industry conferences million clinical reports breakthrough device designation one million reports delivered breakthrough device designation received foundationone portfolio comprehensive foundationone tracker circulating genomic profiling cgp tests tumour dna ctdna detection molecular monitoring assay foundation medicine milestones partnership epic patient profiles first customer part partnership linked patient profiles epics electronic medical record emr foundation medicine flatiron health system went live clinicogenomic database cgdbaccess healthcare working collaboration global local stakeholders support governments efforts build strong resilient healthcare systems particularly people low lowermiddleincome countries every countrys healthcare system unique work closely partners develop deliver tailored solutions un sdgs material topics longterm mindset availability healthcaredr eric ngyedu chief executive officer cape coast teaching hospital cape coast ghana newly opened cancer treatment centre ghana dr ngyedu focused addressing challenges cancer patients face journey grateful power partnerships directly benefit patientsaccess healthcare roche dr roberto altamirano gynaecologic oncologist santiago chile dr altamirano played key role advising ministry health chile evolution towards hpv testing cervical cancer screening critical prevention strategy important step towards eradicating disease country dr eric ngyeduaccess healthcare roche breaking barriers cancer care ghana throughout dr eric ngyedus career spent across country partnership great deal time effort improving already starting address geographic access health people ghana training barriers quality cancer care support capacity become oral maxillofacial surgeon santa building training healthcare workers clara cuba dr ngyedu returned home ghana support awareness creation communities around soon found could make country biggest impact community delivering improving care ghanaians cancer centre opened two public hospitals ghana mandated today dr ngyedu chief executive officer provide cancer services facilities cape coast teaching hospital ccth often overburdened leading delays patient west coast ghana hospital world access specialised care says dr ngyedu class leader tertiary healthcare well bode well managing outcomes medical research serves training ground worsens patients prognosis financial hardships undergraduate postgraduate training presented long travels also worsen plight medical health professionals patients knew crucial curb hospital also site new cancer challenges establishing new centre treatment centre cancer one service patients within outside region significant public health challenges ghana new cases diagnosed centre provides infrastructure people dying disease space oncology patients treated also treatments oncology pharmacy ghanaians face numerous challenges cold room established well support patient journey including health mental provision quality medicines reagents social financial hurdles explains dr ngyedu used diagnosis treatment limited infrastructure limited access comprehensive treatment centres limited unique partnership access affordable cancer medicines roche long working improve oncology challenges put together mean patients care ghana dr ngyedu grateful experiencing harrowing journey partnerships like one directly benefits patients partnership roche unique addressing significant public health one patientcentred challenge products supporting patient care thanks partnership roche breaking barriers cancer patients face government ghana work begun develop says private sector critical role infrastructure deliver cancer care key play increasing access care people hospitals across country ccth one three ghana need partnerships like move new treatment centres opened needle make meaningful change international agency research cancer world health organization ghana fact sheet partnership roche unique one patientcentred products supporting patient care breaking barriers one meaningful change partnership large portion population lives brought increased screening remote areas need find way provide treatment breast cancer patients year care telemedicine absolutely possible breast cancer awareness month october care cancer patients distance able screen people breast need technology place partnerships cancer support received private sector helped us get roche providing infrastructure today continue able cost patients says future look role technology dr ngyedu additionally roche working play government enable public funding key cancer treatments testament roche made longterm commitment impact partnerships ghana african continent continue invest strengthening health systems sustainable future collaborating partners implement innovative although tides beginning turn patients solutions tailored specific needs ghana still many opportunities patients region dr ngyedu brings pave way increased access care hope future healthcare ghana future leveraging technology provide care patient centre cancer patients critical reflects dr ngyedu always right thingaccess healthcare roche cape coast teaching hospital home new cancer treatment centre increased access screening treatment patients ghana dr ngyedu believes cancer care continue evolve thanks new technologies partnerships private sector leading critical evolution cervical cancer prevention chile throughout life dr roberto altamirano evolution towards improved prevention understood importance good health cervical cancer guidelines evolved passionate helping people making years critical milestone difference passion led achieved ministry health chile medicine specifically gynaecologic oncology introduced pilot project implement hpv wanted surgeon testing health services wanted see treat patient whole good health system needed make person main goal help others upgrade pap test limitations impact community says dr altamirano recently dr altamirano made significant advisor ministry progress towards goal playing role advocating hpv testing many years ive changing health system improving putting forward since explains cervical cancer screening chile started working mentors improve health system shared vision longstanding process screening help many people possible best way since chile national cervical change conduct screening cancer screening programme pap enable better prevention persistent test used standard identify women need hpv testing risk programme reduced mortality rates time women continue diagnosed chile among countries moving towards preventable disease suggesting screening programme hpv primary hasnt effective early detection test eligible women line world health could almost cervical cancer organization recommendations cases women havent done kind screening strategy aims better identify test missed opportunity prevention risk disease order prevent invasive cancer explains dr altamirano developing despite almost preventable overcoming barriers adoption vaccination screening treatment cervical programme first introduced cancer claims lives women several barriers prevented women every year making one leading causes screened says dr altamirano biggest cancer deaths women human papillomavirus hpv problem lot women dont get tested known cause nearly cases cervical think dont need dont cancer finding treating precancerous time think going hurt disease cancer develops important opportunity screening often missed prevention strategy cervical cancer fact sheet world health organization cervical cancer screening individuals average risk guideline update american cancer society implementacin del diagnstico molecular del vph experiencia chilena en curso revista mdica de chile global strategy accelerate elimination cervical cancer public health problem world health organizationaccess healthcare roche dr roberto altamirano dr roberto altamirano key advocate pilot programme chile emphasises hpv testing primary screening method eligible women important strategy prevent cervical cancer continues mission raise awareness education hpv importance cervical cancer screening women power knowledge take care themselvesaccess healthcare roche believe best giving people power knowledge take care needed increase awareness hpv keep screening women every year teach patients importance prevention relatively confident woman says education critical patients negative hpv test low risk developing also healthcare professionals cervical cancer focus ensuring werent comfortable talking hpv women screened identify accustomed pap test higher risk addition providing hpv test health also believes programme critical services pilot programme roche worked step help country meet whos goal partners train primary healthcare eradicating cervical cancer within next century providers collect samples supported im dreamer try stay positive education programmes increase awareness think going work says hpv importance screening change need time keep insisting prevention dr altamirano believes crucial every day right thing help bring healthcare professionals board achieve goal eliminate disease new screening method explaining went teaching programme ongoing thirst knowledge learned perform hpv test adapted today dr altamirano entrenched chilean really well change health system selfproclaimed multitasker practising gynaecologic oncologist public also seen impact among patients private healthcare member education women chilean society obstetrics gynaecology started asking test people becoming advisor ministry health recently involved seeking information starting expanding knowledge area earning know hpv masters health administration also assistant professor obstetrics gynaecology chiles national ambition university chile today around women screened programme ministry health remains committed goal plans expand hpv testing health services helping others years chile ultimate goal achieve national experience passionate access eligible women educating patients next generation gynaecologic oncologists believe dr altamirano thinks hpv testing place best giving people power knowledge women reached hpv test take care done every five years means dont power partnerships roche know diagnostics nordisk global local partners medicines positively impact lives publicprivate partnership reached reach people need every children countries since country unique challenges tunisia vietnam joining project comes accessing healthcare something varies dramatically country country initiatives increase access medicines funding infrastructure healthcare capacity low lowermiddleincome countries disease awareness play role also delighted renew long firmly believe need take holistic standing partnership world federation collaborative approach address potential hemophilia partnership barriers challenges simply complex patients haemophilia low single party solve alone lowermiddleincome countries reached aid programmes addition hundreds increasing access diagnostics around healthcare professionals trained world testing capacity enabled expanded past decade publicprivate partnerships strengthened laboratory additionally proud become systems african nations highly impacted member access oncology medicines hivaids built institutional capacity atom coalition new global partnership led regional national partners improved union international cancer control quality diagnostic services across continent increase access qualityassured essential together efforts improved millions cancer medicines low lowermiddleincome lives example worked partnership countries help countries develop us presidents emergency plan aids capacity proper use including training relief pepfar scale hiv viral load testing diagnostics partnership complement early infant diagnosis may existing goal double number patients entered new partnership global fund receiving innovative therapies low build local capacity tackle fundamental lowermiddleincome countries end infrastructure challenges generating goal aims overcome many barriers delivering diagnostic results managing patients face lowincome countries healthcare waste lack infrastructure well economic pressures regulatory challenges addressing diabetes access barriers disparities worldwide small summary initiatives publicprivate partnerships critical developing working expand access healthcare sustainable access initiatives something around world partnerships sit seen diabetes together heart access work partners roche plays part addressing continue work closely public private diabetes access barriers disparities worldwide nongovernmental organisations broaden changing diabetes children access healthcare diagnostics programme run roche diabetes care novo medicinesaccess healthcare roche million hivpositive patients children able viral load monitored countries reached global access program check changing diabetes children programme treatment efficacy partnership novo nordisk since launch people patients screened diabetes next low lowermiddleincome countries two years meru kenya mwanga accessed core medicines access project access projects billion tests roche ranked th around world conducted roche worldwide access diagnostics products medicine index around women people low lowermiddleincome countries helped last year genentech access screened cervical cancer medicines need free medicine support roches global access program provided people double compared cities million people continue work city cancer challenge roche patient support programmes active cities worldwide reaching increase estimated million peoplepeople culture believe personalised approaches achieve best outcomes patients true employees strive identify create opportunities unique cultivate environment enables people bring unique selves roche achieve best work behalf patients un sdgs material topics talent attraction retention organisational agility patient centricitycris wilbur chief people officer basel switzerland cris believes employees aligned towards shared purpose feel comfortable sharing views support resources need truly make difference lives patientspeople culture roche lorice scalise general manager roche pharmaceuticals buenos aires argentina leader lorice understands increasing access healthcare begins understanding valuing diversity individuals also requires roche leadership workforce reflect diversity cris wilburpeople culture roche helping teams keep patients centre everything cris wilbur roches chief people officer effectively together going able firm believer roche employees play bring solutions faster patients customers critical role shaping fostering right culture order meet commitments patients end goal mind first roche may different divisions operating principle solely patients operate different geographies best really spotlights always clear sense shared vision commitment making patients focal purpose point everything cris explains time corporate executive operating principle says committee realised important put patients first makes clear opportunity develop aligned principles expect every single person company reflect unique roche culture also says keep patients top mind empowering entire company remain focused manifests things innovation making even focus understanding need difference patients society beginning roche group operating principles born integrating company culture process creating principles worthwhile journey clear focus ensuring would operating principles eight seemingly simple positive impact larger culture statements goal guiding work roche nice company cris explains together different parts organisation thats important incredible things lot meaning thought behind together really like individual principle well set principles operating principles enable us supportive bringing together required input also feeling comfortable colleagues across organisation ensure bringing different views debate principles resonated people also fosters innovation much quickly inspired challenged think work new ways cris adds also help us hold accountable become better teammates privilege part process says colleagues partners enable people cris organisation transforming bring full selves conversation become agile working celebrated make okay differently needed come together around agree disagree colleagues single set principles looks like truly embracing others differences practice ultimately able work integral part culture keep patients top mind manifests things focus understanding need beginning aligning future ambitions ask another colleague simplify roches longterm ambitions drive work radically project thinking every day operating principles serve longterm seeing critical tool make goals reality principles truly helping us prioritise set clear help different parts organisation work areas focus work towards shared together effectively make bigger purpose says cris tremendously sustainable impact principles help us inspiring become even innovative collaborative company without losing sight biggest goals surprise passion cris says even outside work criss interests include quantum computing reinforce belief principles put place longevity continuous improvement focus future mind dont want way work find potential fascinating try keep constantly changing says cris sense new developments cris says quantum permanence enable people across company computing could help us solve biggest develop approaches work firmly rooted problems improving supply chain logistics shared purpose shared ways working accurately forecasting weather may even confident track long time able help us greatly reduce time costs come needed develop new drugs months following rollout operating whatever future may look like cris principles clear people beginning confident increasingly complex world live common hear colleague roche remains focused right thingspeople culture roche culture roche centred shared purpose making meaningful difference patients society new operating principles unite employees work together achieve goal embracing uniqueness individual leader unique patients serves spend minutes lorice scalise overcome biases explained general manager roche pharmaceuticals able really see everyones argentina immediately sense achievements clearly lorice conversation passion people passion part turning point makes lorice exceptional leader effective advocate improving access healthcare new focus diversity inclusion enabled lorice understands success expanding lorice stop putting energy access begins understanding valuing person thought others expected diversity individuals also requires become comfortable simply roche leadership reflects diversity newfound freedom made effective job explains realised across years roche lorice trust connect emotions witnessed substantial increase intuition work saw much companys commitment building diverse potential blocking took steps inclusive leadership culture also remove obstacles put way seen commitment better equip company meet diverse needs vast since companys approach diversity world patients inclusion evolved significantly today talk new level lorice says evolution impacted lorices leadership know dont consider different style roche decided focus perspectives people involved work diverse inclusive empowered including cultural economic religious aspects bring true selves work changed effectively serve purpose helping way us leadership positions viewed patients missions work lived day important seat table initial hesitancy lorice genuine passion listening roche first announced commitments truly interested others say increase number women leadership qualities critical member lorice shocked emphatically explains roche diversity inclusion di council didnt want part quota wanted part di council great achievement valued achievements gender explains latin american region underrepresented initial efforts put place people really roche ceo severin schwan visited brazil lorice shared concerns severin said di council focused range understood feelings needed initiatives including increasing talent pipeline make change company could begin underrepresented countries making clinicalpeople culture roche lorice scalise leader lorice understands increasing access healthcare begins understanding valuing diversity individuals also requires roche leadership workforce reflect diversitypeople culture roche enough latest innovations regulatory approvals remove barriers including social cultural economic trials inclusive increasing health equity screening hpv virus cause women took seat committed giving cervical cancer clear example know voice underrepresented countries people many reasons women many places lorice says im share thoughts unable unwilling see physician lorice help challenge status quo broaden says determined help protect companys perspective women cancer needed develop selfadministered hpv test pay still done attention unique aspects cultures course lorice understands obstacles serve understand specific fully diverse inclusive leadership still exist types innovations needed lorice cautions belief goals believes roche responsibility lead declarations place company mission expand healthcare access people done necessary groundwork knows parts world understanding everything subject situation different needs biologies cultures always changing always new reactions treatments things learn understand lorice explains leading example finally lorice seeks dispel belief lorices commitment improving diversity diversity inclusion simply two different inclusion roche deeply rooted words thing explains personal beliefs walk walk explains distinction diverse group im single mom two boys giri took people various places cultures first english class age asked feedback different beliefs dont value accept worked hard development ideas discount say help mentors living proof dont speak perfect english example always overcome barriers biases inclusive diversity first step inclusion vital lorice equally passionate life outside second step office wake every morning excited day bring says family connecting access diversity friends ground give confidence lorice firmly believes science innovation fight battle cheering achieve purpose reach shes leading charge diverse everyone enough latest inclusive workforce office innovations regulatory approvals explains find adventure three kids remove barriers including social lost book exploring yet another new world cultural economic unique individuals supporting engaging people year left mark multiple ways global live well team knows ever finally overcome pandemic moved important take care endemic state allowed us start care others global returning spending time office live well programme focused mental health wherever possible time new challenges guiding theme throughout year revealed form political tensions dedicated wellbeing days offered covering conflicts different parts world well different aspects mental health including inflation potential energy shortage europe boost energy mindfulness resilience mental health awareness neurodiversity since run biyearly global gratefulness employee opinion survey geos measuring engaged happy employees work leading learning last cycle continued check networked ways working require everyone workforce sense engagement efforts build capability lead learn moving right direction includes first foremost selfleadership approximately small large affiliates across learning mindset roche employees roche conducted regular geos pulse surveys globally completed hours learning pleased see continued engagement training internal learning platform activities paying people happy working roche despite many challenges addition implies safe environment faced last several years culture based shared set values leadership commitments collaboration framework carried livingwage analysis underpin purpose february countries roche operates launched new global set operating analysis showed countries roche pays principles define work together employees living wage achieve longterm ambitions single set continue regularly monitor future principles extremely well received employees replaced divisional ongoing focus safety wellbeing functional principles previously developed people purpose centred serving patients continued support society employer care leaders employees enhance advance people safety wellbeing especially leadership skills various times escalating political threats conflicts dedicated leadership programmes also therefore put employee assistance invested curriculum senior leadership programmes place special focus programme prepared launch managing mental stress health offered symbiosis sequel kinesis synergy financial support employees conflict regions early people culture roche employees region north america asia parttime africa australianew zealand fulltime latin america europe pharmaceuticals pharmaceuticals diagnostics diagnostics corporate group functions chugai chugai employees divisionodg training hours supervisory organisation employee health safety total number lost time incidents lost time incidents frequency rate number employees expressed fulltime equivalents operating divisional group business unit department diversity inclusion personal diversity inclusion di heart target achieving share roches strategy deliver personalised care women executive positions patients across world starts us represented nationalities executive positions together embrace unique power person transform lives patients ensuring everyone society every individual roche role play best work thrive roche place people accepted addressing unmet needs diverse patients without compromise true selves communities embrace different ways working styles focus di patient pillar leadership driver innovation expansion advancing inclusive research provided wide range learning opportunities air practices principles across company di accessible employees across support public position statement world employees air expanded inclusive research participated site alliance strengthened partnerships healthcare providers across communities addition external pledges embedding inclusive research heart roche signalled commitment development life cycle teams improving health inclusive culture signing valuable pledge outcomes patients core purpose supporting disability inclusion workplace increasingly diverse world around us time commitment different dimensions diversity research clinical development strength inclusive culture empowered ensure greater inclusion across racial ethnic collective efforts diversity groups support optimising health outcomes networks roche coming together drive di patients worldwide vision forward building workforce reflects societies advancing positive change society serve believe ability advance positive change achieving purpose requires ability society goes far beyond business sustainably creative leveraging broad spectrum enabling equitable access science ideas bring meaningful solutions technology engineering mathematics stem patients healthcare ecosystem opportunities realworld science biotech efforts people pillar focused skills hope help grow next generation achieving representation global society innovators investing partnering employees representing communities diverse companies share commitment part di foster greater equity society scale positive change topics di essential achieving longterm society go far beyond roche even healthcare ambitions including diversity leadership building equitable diverse inclusive mirrors workforce globally set future allpeople culture roche global di corporate goals set target achieving share women executive positions underrepresented nationalities executive positions per q baseline additionally invite leaders across roche make additional commitment relevant local culture context women underrepresented nationalities q q q q q q q q goal diversity networks chapters around globe agegeneration raceethnicity disability gender lgbtq di veterans intersectional diversity networks grassroots selforganised groups employees coming together contribute di mission organisation specifically aimed embracing unique power person transform lives patients society includes individuals countries asia latin america eastern europe middle east africa e xcludes chugai workday lite companies companies use roche workday system leading hr system due arms length alliance mergeracquisition agreementsenvironment know climate change one largest global challenges must address matter urgency years teams implementing programmes help us reduce greenhouse gas ghg emissions zero un sdgs material topics energy efficiency longterm mindsetthomas wolf chief environmental sustainability officer basel switzerland thomass love nature passion environmental protection led career path thirty years later passion fuels work developing roches climate change mitigation strategyenvironment roche nerina itin environmental specialist rotkreuz switzerland nerinas work allows contribute development local environmental strategies also engage colleagues contribute individually sites environmental goals thomas wolfenvironment roche steering towards sustainable energy future growing small town rural nahe valley issues climate change working west germany thomas wolf spent much towards sustainable energy future many years childhood outdoors exploring nature area delaying waiting others find meaningful home vast rolling hills forests vineyards solutions could result dramatic backdrop many disruptive expensive changes future adventures young boy typical thomas explains proud roche childhood experience going school playing delay taking action past sports friends spending much spare well way achieving goal time outdoors explains really beginning love nature passion implemented carbon environmental protection dioxide reduction measures led decrease carbon dioxide generated within along childhood passion outdoors operations world emissions rose thomas credits chemistry teacher period goal achieve driving force behind interests science reduction engineering learning compared asked many good career prospects area able achieve targets attended university karlsruhe today continue ensure moving towards karlsruhe institute technology graduated thomass answer simple one clear degree chemical engineering well thoughtout strategy together enthusiastic long graduated thomass career engaged teams develop implement roche began global engineering department plans make happen former vitamins division years later putting passions takes village good use role chief environmental order develop implement strategy sustainability officer im fortunate result meaningful change must career help fight climate change collaborate internal well external shaping roches climate change mitigation strategy stakeholders partners says thomas technical background definitely huge asset knowledge sharing impact efforts work says thomas amplified across network group functions local sites global energy summit towards sustainable energy future taken place annually past years environmental goal ambitious reduce critical element fostering close greenhouse gas ghg emissions zero community subject matter experts share like company roche requires energy passion meeting roches environmental goals operate order address energyrelated conscientious sustainable way site different considerations capabilities priorities must maintain open lines communication collaboration along way roche sites around world goal requires diligent planning today keep working closely community imperative momentum continue see especially sites focused tangible results efforts things although developed global strategy overarching targets moving duty contribute work towards sites must develop roadmaps area long great towards sustainable energy future site community enthusiastic experts actively different considerations capabilities priorities contributing support leadership must maintain open lines communication make mark says collaboration along way says thomas optimising vehicle fleet performance may asked one thing us important one site example optimising collectively make difference thomas energy use manufacturing may important swift clear answer mindful consumption feasible another whether reducing consumption materials resources like energy water future sustainable reusing recycling materials things according thomas future indeed positive impact along entire value bright one organisation worked tirelessly chain already experiencing dramatic past two decades establish consequences climate change realise governance strategy environmental climate change one biggest risks initiatives stipulate guidelines directives planet consequences failing mitigate set ambitious targets implement monitoring enormous social environmental mechanisms put together teams passionate financial systems appreciate people dedicated making impact role play actions take help mitigate see better future goals without plan wish says generations come thomas meeting longterm zeroemissionenvironment roche thomass passion sustainability driving force behind year tenure roche helps ensure climate mitigation strategy driving us towards goal reducing greenhouse gas emissions zero environmental protection challenging achievable completing bachelors degrees clear measurable goals sometimes environmental engineering many nerina technical measures put itins classmates went pursue careers working place engaging employees nongovernmental organisations although areas reducing business flights seemed like logical choice given many make difference environmental groups active around world nerina took different approach felt ambitious goals could contribute company specific goals roadmap team environment main business rotkreuz developed indeed ambitious impressed work roche already one stands particular reduction area environmental protection felt fossil fuels heating warm water zero could put knowledge skills good yes ambitious goal use easy decision applied definitely achievable explains nerina internship thrilled offered already able ensure role says nerina electricity comes sustainable sources reach even higher making impact past four years nerina indeed another area focus site business flight making impact developing implementing reduction promotion alternative forms various programmes environmental specialist collaboration transportation around diagnostics site rotkreuz switzerland employees site contribution site home central diagnostics customer clear impactful way help achieve goals areas functions including research nerina team driving towards adds development production logistics nerinas matter small may seem says nerina work allows contribute thats employee engagement important development local environmental strategies us know impact make roadmaps also engage rotkreuz contribute employees contribute individually sites environmental goals collaborating sites global safety security health environment protection one person one department team also instrumental component nerinas makes difference site services lay work sharing knowledge best practices groundwork everyone empowered entire community learn challenge encouraged take action really one work new ways try new things main strategies implement sustainability goal incremental improvements everything nerina explains year yearenvironment roche nerina itin diagnostics site rotkreuz nerina helps engage employees help us achieve sustainability goals around people working site contributions make significant impact efforts towards sustainable energy futureenvironment roche sustainability something people genuinely care see increasing time people become aware look future commitment came doesnt hesitate considering future holds explain comes environmental protection roches work area nerina hopeful mother environmental teacher growing greatly influenced sustainability something people genuinely interest area also spent much care see increasing childhood involved scouts love time people become aware nerina says nature outdoors almost destined think sustainable energy future absolutely beginning possible matter get roche achieved lot need nerina looks forward challenging work keep going ahead studies work roche far enjoy working field long future nerina following feel still contributing long passion continuing study area possibly im constantly learning looking currently working towards masters degree solutions complex problems take environment natural resources hopes mindset behavioural changes society developing knowledge bring meaningful change play role skills valuable work roche big small continue asked lifelong passion long future embracing environmental responsibilities environmental protection intrinsic part total environmental impact per employee roches business approach decreased approximately sense responsibility methodically continued reduction greenhouse gas ghg approach issues concerning quality productivity emissions decrease amount waste costefficiency continuously monitor positive effect environmental impact environmental performance aim collect data least key performance indicator responsible approach energy usage ensure compliance high using natural resources sustainable manner standards objectives guarantee fundamental roches environmental strategy processes equipment state art large proportion energy use still comes fossil fuels result produce ghg environmental risks mitigated via system mainly carbon dioxide waste products prevention successful environmental risk contribute climate change air pollution management system companys environmental minimising negative impact involves actively programme operational strategies covering contributing sustainable energy future climate change mitigation reducing emissions includes reducing energy consumption increasing increasing resource efficiency environmental efficiency implementing innovative technologies aspects procurement water waste increasing use sustainable energy management complement strategies scope energy consumption per setting tangible quantitative mediumterm employee decreased reduction longterm goals achieved implementing energysaving measures reducing amount fuel use heat ecobalance cool operate sites roche measures environmental impact using ecobalance metric greenhouse gas emissions climate change established groupwide goal reduction environmental sustainability climate change levels ecobalance refers mitigation go hand hand critical consumption energy resources global issues understand business emissions waste business activities challenges related climate change describes total environmental impact managing risks part environmental operations allocating environmental impact risk management programme longterm points ecologically relevant parameters goal reduce ghg emissions net zero consumption natural resources later validate new targets emissions air water soil obtain view science based targets initiative sbti environmental pressure place significant part ghg emissions originate earths ecosystems points added transformation use energy related total number employees energy reduction achievements enables us monitor ecological impact paralleled reduction scope per employee ghg emissions per employeeenvironment roche water consumption noise pollution landfilled waste energy consumption emissions water roche emissions air ecobalance vehicles operate using electricity energy sustainable sources company vehicles look ways reduce energy consumption improve energy efficiency energy use aim using renewable selected types electricity business air travelling video teleconferencing facilities natural gas established sites widely used employees encouraged use trains consolidate several business trips one scope scope market based capital goods scope scope scope ghg emissions ghg emissions ghg emissions co co co purchased goods scope scope services scope market based fuel energyrelated activities upstream transportation waste generated operations business travel use sold products direct emissions within operations indirect emissions purchased energy emissions resulting activities within supply chain calculation methodology based ghg protocol following hybrid activitybased approach approach refinement numbers comparable published annual reportenvironment roche energy consumption terajoules total scope scope marked based energy scope scope marked based consumption gjemployee gj gigajoule halogenated hydrocarbons tonnes inventory releases global inventory including chugai genentech ventana includes data additional roche sites well wider scope halogenated hydrocarbons previous years emissions air tonnes vocs particulates nitrogen oxides sulphur dioxide volatile organic compounds water usage discharge water withdrawn million water consumed million organic matter discharged waterways treatment heavy metals discharged waterways treatment kg landfilled incinerated waste tonnes nonhazardous hazardous contaminated soil hazardous construction waste nonhazardous high remediation activities kesslergrube germany limited activities increase hazardous waste due reallocation electronic waste hazardous waste environmental data spark therapeutics flatiron health foundation medicine included roche environmental resultscommunity engagement tradition philanthropy existed roche century philanthropic efforts united common purpose make lasting impact building stronger healthier communities global citizens supporting local efforts un sdgs material topics longterm mindset availability healthcarelucia erniawati access communications health system value strategy lead jakarta indonesia role roche indonesia lucia saw potential improve outcomes patients living cancer helping oncology nurses education gain recognition key partner patient carecommunity engagement roche margareth lasut oncology nurse north sulawesi indonesia margareth one first nurses enrolled indonesias new oncology nurse specialist training programme already looking forward difference new expertise make cancer patients lucia erniawaticommunity engagement roche bold vision big impact whenever thinking new initiative another making difficult develop specialist biggest question us always impact could knowledge required provide effective society find answer care saw opportunity make real partners agree makes finding common longlasting impact ground get much easier nursing workforce also challenged lucia erniawati chapter lead access imbalanced distribution across regions meaning communications health system value strategy many regions country underserved roche indonesia talking importance healthcare professionals significant identifying bold vision unite partners lack nurses specific oncology expertise different goals perspectives lucia team saw potential country like indonesia hugely special focus cancer care nursing decided complex health infrastructure needs support catalyse launch first specialised million people across islands spanning oncology training nurses indonesia three time zones potential impact bold partnerships significant partnerships mean progress bold vision place team needed take ongoing project train specialist oncology gain buyin stakeholders included nurses example indonesian ministry health indonesia university dharmais national cancer center cancer survival rates indonesia significantly oncology nursing association lower developed countries due low awareness poor diagnostic capabilities although partner perspectives lack specialised care facilities exploring goals agreed potential benefit pain points along patient continuum training oncology nurses could significant care lucia team realised scale together began working implement plan problems compounded absence core scholarship programme supported specialised nurses provide care patients roche corporate donations philanthropy cancer emerging market scholarships programme train oncology nurses indonesia university help oncology nurses play important role develop countryspecific cancer care helping patients throughout entire journey research suggested majority progress already significant nurses learn deal complexities cancer basic oncology nursing training curriculum treatment palliative care job says accredited ministry health programme addition due competing healthcare priorities trainers certified nurses certified often rotated one position basic oncology nursing training students thats corporate donations philanthropy work best standalone grant starting point catalyst real meaningful change enrolled threeyear oncology nurse programmes also supported specialist training programme global corporate donations philanthropy team ultimately goal always donation future goals include placing oncology nurse partnership collaboration becomes specialist every one archipelagos selfsustaining one core values provinces opening five new training centres comes roche philanthropic initiatives establishing oncology nurse specialist programmes universities established centre excellence one momentum really starting build worst affected areas stunting country also served proof concept significance initiative partners regions says another regional fully invested vision oncology nurses government quickly committed adopting longterm solution spreading project area could clearly word project growing almost see benefit programme taking life says lucia able act instigator catalyst standalone grant starting point ongoing partner established centre catalyst real meaningful change linked key policymaker potential partners access care could personal passion grow throughout country centre could years roche lucia proud ensure ongoing longterm sustainability involved several catalysts change throughout indonesia include effort lucias passion make impact extends rebuild healthcare centres large fundraising activities including cooking earthquake programme reduce raise funds annual roche childrens percentage children affected childhood walk companys largest employeedriven stunting significant issue indonesia many philanthropic event low lowermiddleincome countries lucia highlights whether work home want make latter programme another great example difference says likeminded people projects quickly build momentum come together achieve amazing thingscommunity engagement roche lucia always passionate uniting partners around meaningful goal helping establish oncology nursing scholarship indonesia helping set centre excellence reduce childhood stunting lucia knows collaborating others truly make difference bringing specialised oncology nursing home margareth lasut quite literally born journey begins medical profession throughout childhood margareth applied programme indonesias north sulawesi province saw quickly accepted fellow scholarship mother dedicated nurse make difference recipients travelled around country lives countless patients even young jakarta begin studies september girl margareth knew wanted follow footsteps programme interactive interesting says limits us express didnt know early days learn impact many people large important impact could possible continually working improve community could really knowledge skills seeing need seeking solution many new concepts margareth margareth became registered nurse studying cites care continuum one quickly realised wanted help interesting helpful ive learned patients access highest levels care cancer nurse dont treat patient well aware care cancer patients north theyve arrived hospital diagnosis sulawesi needed improvement hospital explains start even margareth worked largest region cancer treatments begin prevention early stages developing first cancer unit detection provide specialised care way rehabilitation stage endoflife early margareths supervisor told experience outcome firstofitskind programme provide scholarships specialised oncology nursing another aspect love programme learned programme opportunity visit hospitals developed university indonesia jakarta see eyes advanced supported roche accepting applications cancer care looks like much margareth immediately knew found way improve care back home says improve quality care people community bringing benefits home margareth returns north sulawesi programme answered prayer training complete among margareth explains gave opportunity first oncology nursing specialists province expand nursing knowledge one population million people best educational institutions indonesia already looking forward difference bring knowledge back colleagues new expertise make cancer patients ultimately help patients families explains every year number cancer entire community patients region increasing hope becommunity engagement roche margareth lasut one first students enrolled oncology nurse specialist training programme margareth knows plays role helping educate nurses care living cancer believes education key component helping alleviate overburdened healthcare system indonesiacommunity engagement roche first thought patients would learn realised one would learning able give many access believes scholarship programme combined quality care understanding many benefits oncology nursing specialists provide lead also want share new knowledge continued increase nursing specialists hospitals nurses encourage continue across indonesia asked hopes education well cancer treatment future margareth says think hope north sulawesi continue improve far use knowledge change peoples lives future first margareth looking forward completing increasing number oncology nursing studies returning home husband specialists throughout indonesia hopefully family spending quiet evenings home help alleviate overburdened state healthcare asked surprised working system margareth explains know cancer patients replies first thought adding even one oncology nursing specialist patients would learn realised hospital staff lower overall cost treating one would learning cancer patients nurse help educate theyve taught importance family colleagues turn increase access shown maintain hope care patients difficult times focused community impact philanthropy done well catalyst years ahead supporting wide range meaningful sustainable change mindset scholarships emerging markets see table core philanthropic strategy opening paths new possibilities organised around four key pillars humanitarian education new nurses health support community projects education workers lab technicians many programmes cultural collaborations bolstered employee engagement take multistakeholder approach trusted believe longterm sustainability partners ground make philanthropic societal change relies upon engagement ambitions reality along way ensure local communities mantra extends projects initiatives support meet employees fact largest employee quality innovation sustainability criteria engagement philanthropic event began employeedriven pilot across three contributing healthier communities sites roche childrens walk many philanthropic initiatives help build sites participated campaign across stronger healthier communities live countries garnering support work beyond example employees together supported supporting international committee local projects global projects red cross icrc years roche employee action charity trust longeststanding partnership spanning nearly react long founding company continued evolve ever since major focus every year group engaged recent years helping improve access employees around world selected water mali lack access vital childrens walk ambassadors witness resource acute due protracted conflict impact employee fundraising activities firsthand drought limited resources following threeyear pause due covid people benefitted initiative pandemic ambassadors visited several react projects also help bolster community access basic primary healthcare services included childs dream cambodia supporting transnet phelophepa healthcare foundation dedicated improving childrens trains since providing services education support helping build evolved meet pressing health needs schools outfit computer labs provide rural communities south africa scholarships selam childrens village phelophepa provided healthcare services ethiopia supporting five orphan patients training community homes children difficult healthcare volunteers food gardens start life mothers mothers malawi enable food security region support helps improve health wellbeing adolescent girls hivpositive perhaps better example sustainable hivexposed unicef malawi change providing people training helping keep girls school needed build healthier communities menstrual health hygiene campaigncommunity engagement roche philanthropic contributions roche group around world corporate donations philanthropy cdp fondation roche recherche en afrique frra roche employee action charity trust react local philanthropic projects global emerging market scholarships programme cdp corporate donations philantropy frra fopnhildanathtrioopicn roche recherche en afrique country recipient organisation discipline scholars react roche employee action charity trust cambodia childs dream react high school local philantrophy universit atlantique frra lab technicians unit de formation et de recherche cte divoire sciences mdicales dabidjan frra pathologists ethiopia selam react vocational ao alliance frra trauma orthopaedic ghana college nurses midwives frra oncology nursing ghana eth zrich foundation frra mechatronics engineering india kiran cdp university indonesia universitas indonesia cdp oncology nursing amref frra community health workers kenya beyond zero cdp nursing christel house cdp middle school south africa maharishi institute cdp business peru colombia el salvador guatemala fundacin educacin cdp business total patients received healthcare services phelophepa south africa people benefitted icrcs access water initiative mali employees supported roche childrens walk illustrative map recipient countries exhaustivebusiness ethics believe integrity basis sustainable successful business every employee responsibility behave integrity accordance shared values compliance guidelines also expect partners work meet integrity standards un sdgs material topics human rights ethics transparency patient centricity availability healthcare complianceli bao regional sales lead beijing china li knows critical diagnostics accessible people places responsibility keep latest developments diagnostic technology regulations govern thembusiness ethics roche matteo alaria head product sustainability sartorius torino italy matteo responsible driving sartoriuss sustainability efforts ensuring clients like roche look opportunities reduce resources energy use implement sustainable solutions li baobusiness ethics roche transforming business model better serve patients role regional sales lead roche arrangement roche responsible diagnostics china li bao knows well keeping ensuring instruments working advancements diagnostics order repairing replacing machines instruments process ongoing task needed return reagent portion also understands importance expanding contracts provided company access advancement many people predictable source revenue time possible thats works hard stay current industrystandard model supported growing latest developments diagnostic technology healthcare industry whatever necessary ensure available people places healthcare market particularly diagnostic sector underwent rapid growth task connecting people roche china chinese government began question diagnostic tools also entails keeping whether particular model actually changes regulations govern best patients national medical impending regulatory change china products administration nmpa determined necessitated complete transformation way separating financial arrangement large portion company business li knew diagnostic instruments financial entire team faced particularly difficult test arrangement reagents would increase agility allowing hospitals quickly adopt new instruments years experience roche diagnostics technologies better experience responsibility core line business li patients new regulations take effect comfortable professional challenges beginning transition period regulatory change major transformation several years critical business process room error li team quickly saw understanding challenge likely demanding journey regulatory change might necessary thing also right seemed simple surface actually thing substantial modification way roche competitors business li team shifting needs growing market tasked ensuring compliance regulatory change hospitals new regulations smooth possible healthcare facilities would typically lease diagnostic instruments part agreements first reaction roche within facility would commit purchasing specific larger industry confusion explains li amount reagent substance used conduct nobody understood rationale gain clarity diagnostic test produce result order roche team began talk regulators ask instrument provided period questions work develop clearer idea contract would required making changes part investment country part commitment providing access quality healthcare people benefits patients included increased instruments review thousands existing transparency access new technologies contracts find potential issues problems soon became apparent impact roche began develop solutions one one new became evident well li saw arrangements made customers roche offered highquality instruments aligned new regulations reagents exceptional level service new business model unlikely negatively long journey says li able impact operations explains complete transition first came see making changes two years speaking honestly last part investment country part difficult part great deal commitment providing access quality work everyone involved healthcare people transparently complying local regulation keeping compliance centre conducting business ethically compliance task make happen regulations especially change core principle roche li elaborates gathering team value roche places compliance way li immediately sure path everywhere monthly meeting compliance would know would focused compliance even call day truly crossfunctional undertaking compliance day thats update everyone team assembled develop strategy compliance news discuss challenges transformation included representatives facing determine needs done finance legal compliance sales ensure always need departments group began connect external stakeholders including hospitals ready whats next device distributors determine best even massive undertaking nearly complete ways transition new regulations li likely sit still long lifelong minimising disruptions commitment staying healthy active involves swimming jogging basketball badminton large portion work fell sales sons following footsteps showing team worked closely customers great promise swimming part family hospital labs inventory current wide commitment keeping pace lifebusiness ethics roche healthcare system china evolves li colleagues ensuring roche continues provide access quality healthcare people working partners across healthcare system ensuring compliance new regulations minimising disruptions patients healthcare providers demonstrating value sustainability sartorius global supplier innovative constantly pushing technologies services enable roche suppliers find opportunities biotechnology companies simplify less reduce resources energy use accelerate progress biomanufacturing matteo look sustainable solutions every aspect alaria sartoriuss head product sustainability business says matteo end lives breathes sustainability environmental day everyone benefit approach engineer training combined two clients suppliers environment passions throughout career love ultimately patients environment thirst things datarelated value collaboration first job consultant working biomanufacturing industry extremely complex variety industries joining sartorius could see faster progress benefits rewarding experiences helping companies patients increased organisations think act sustainably reflects collaboration simplification many matteo climate change one biggest opportunities speed sustainability challenges face society today efforts across industry need ask must act see changes future questions like better new innovations singleuse technologies faster access patients could explore package sustainability one sartoriuss three corporate product efficiently values along openness enjoyment company takes holistic view finding resource matteo believes roche leader efficient innovative technology solutions biotechnology industry great opportunity help clients translate new scientific pave way comes industry discoveries quickly effective patient collaboration open dialogue suppliers care progressing towards sustainability partners find common ground goals sartorius looks entire value chain industry really embed sustainability across research development manufacturing board roche datadriven company storage transportation medicines says way connect sustainability vaccines speed time takes business find solutions data patients benefit matteos role exactly roche operates business ensure happens sustainability mindset critical future industry core ethical responsibility grateful collaborate roche support access innovative medicines making meaningful change people sustainable way possible matteo saysbusiness ethics roche matteo alaria matteos lifelong passion sustainability propelled explore new innovative ways help clients reduce resources energy use believes companies like roche lead way biotechnology industry help set standard companies move towards sustainable futurebusiness ethics roche way connect sustainability business find solutions data exactly roche operates business knowledge power sartorius taken approach across many matteo team sartorius know indepth functions prior pandemic knowledge clients processes operations appreciative worklife balance integral part providing need role allows spend time family job learn clients still collaborating colleagues clients operate identify right solutions around world reflects matteo mention best possible performance says fact truly sustainable approach matteo degree view helps us working capture opportunities improve sustainability across value chain considering future holds matteo speaks threemonthold daughter living values future whats important thats drives although sartorius headquartered gttingen make difference whatever way look germany matteo works home office forward continuing work clients torino italy grew covid demonstrate value always pandemic sped remote working approaches sustainability heart embedding ethics integrity everything compliance organisations centralised monitoring maintaining strong ethical culture system able free capacity remains main focus comprehensive compliance professionals better support compliance programme also business complex matters focused digitalisation simplification compliance processes controls ensured developed business partner management compliance experts involved earlier checklist provides harmonised approach new business models management external business partners promotes integrity standards globally several initiatives concluded successfully implemented leading early human rights involvement compliance officers also roche respects proactively protects human driving line management ownership rights leveraging current human rights culture integrity compliance times programme moving towards holistic transformation approach value chain include external suppliers human rights programmes harmonised compliance risk opportunity crossfunctional team developed assessment management framework directive human rights due diligence third rolled framework allows us focus parties well updated roche supplier code relevant biggest risks conduct golive date january opportunities well identify potential gaps initiatives increase transparency trends enhance human rights programme beyond roches operations new business ethics incident management system beims successfully implemented one ways ensure compliance allows us capture key data order supplier code conduct better understand root causes noncompliant supplier sustainability assurance visit ssav behaviours trends act upon programme formal riskbased method identifying suppliers risk effort drive awareness engagement sustainabilityrelated violations including across organisation revised launched human rights violations suppliers simplified version behaviour business subject recurring audits ssav directive simpler language easier programme conducted ssavs navigation ensure employees emea apac north america clear understanding key topics including latam human rightsrelated conflict interest corruption observations audited suppliers commit documented corrective action plan address began implementing improved audit findings followup audits conducted standardised process interactions verify corrective actions taken healthcare professionals healthcare adequately address root causesbusiness ethics roche active pharmaceutical ingredients chemicals contract research organisations laboratory supplies logistics transportation human rightsrelated findings per industry waste management cleaning telecommunication temporary labour common critical major findings categories excessive overtime incorrect overtime compensation granted enough numbers days annual leave delayed payment wages compliance employees used roche group speakup line operated external provider available languages countries chief compliance officer received reports alleged violations code conduct via business ethics incident management system unfounded founded still investigation result employment contracts agreements business partners terminated grounds unethical behaviour compared last year higher number reported alleged violations due broadening scope definition business ethics incident removal materiality criteria march corporate governance roche corporate governance corporate governance principles put focus business activities sustainable value creation innovation prescribe management culture conforming recognised standards good corporate governance policy transparent communication material topic compliance principles business activities focus sustainable relevant corporate governance requirements value creation innovation management particular applicable laws swiss stock culture conforming recognised standards exchange six swiss exchange directives good corporate governance policy swiss code best practice corporate transparent communication embody roches governance promulgated swiss business corporate governance principles build federation economiesuisse companys internal basis successful implementation roches governance framework particularly articles commitment serving stakeholders incorporation bylaws embodies principles needed ensure companys strong board directors represents businesses managed supervised interests shareholders manner consistent good corporate governance stakeholders highly skilled managers including necessary checks balances act integrity extremely important printed annual report contains selected links roche ranked one top three roche website httpswwwrochecom sustainable healthcare companies readers thus provided snapshot pharmaceuticals index dow jones company reporting date also sustainability indices djsi th year directed sources consult running recognition based indepth time uptodate information corporate analysis economic social environmental governance roche whereas annual report performance sustainability core covers single financial year ending december business practices award reflects website contains information commitment running business way permanent nature well latest roche news ethical responsible creates longterm companys articles incorporation bylaws value stakeholders curricula vitae current former members board directors corporate executive corporate governance report sets committee published website status structures processes rules roche per end term reporting date takes basis wellfunctioning corporate december year least last governance roche complies five years httpswwwrochecomaboutgovernancecorporate governance roche annual general meeting annual general meeting board directors board directors board committees board committees chairmansnomination committee remuneration committee corporate governance sustainability committee audit committee corporate executive committee corporate executive committee ceo roche ceo roche ceo roche chief financial chief people group pharmaceuticals diagnostics information officer officer enlarged corporate executive enlarged corporate executive committee committee gred pred pharma partnering communications general counsel board directors review agm review reporting year accordance art federal act announced july roche chairman statutory principles federal council dr christoph franz decided stand ordinances combating covid epidemic reelection member chairman covid act art ordinance board directors agm march measures combat coronavirus covid dr franz elected roche board covid ordinance th annual general directors served chairman meeting agm roche holding ltd held since march without shareholders attending person shareholders requested september julie brown stepped exercise rights via independent proxy member roche board directors testaris ag address questions immediate effect accepted company writing management role another pharmaceutical company julie brown elected board agm roche holding ltd march directors march subsequently shareholders reelected dr christoph franz chaired audit committee dr patrick frost chairman board directors term one took chairman audit committee year provided articles incorporation interim basis agm roche holding ltd furthermore agm reelected andr hoffmann julie brown dr jrg duschmal dr patrick frost outlook agm anita hauser prof dr richard p lifton bernard march forthcoming agm poussot dr severin schwan dr claudia board directors nominates dr severin schwan suessmuth dyckerhoff members board new chairman election dr schwan directors term one year provided served member roche board directors articles incorporation since time dr schwan resign member corporate executive committee dr jemilah mahmood elected new member since ceo roche group board directors term one year since addition agm elected dr christoph franz board directors nominates andr hoffmann prof dr richard p lifton remaining members board directors bernard poussot dr patrick frost members reelection recommends following new remuneration committee term one year members election board directors agm prof dr akiko iwasaki sterling organising meeting immediately following professor immunobiology molecular agm board directors determined cellular developmental biology yale structure composition remaining university investigator howard committees shown see also hughes medical institute dr mark schneider board directors chief executive officer nestl corporate executive committeecorporate governance roche moreover board directors nominates board directors dr annette luther dr jrg duschmal anita hauser new appointed head international government andr hoffmann prof dr richard p lifton relations april bernard poussot current members election remuneration committee agm board directors nominates testaris ag election independent proxy agm perolof attinger currently head ceo period conclusion office secretary corporate executive ordinary agm shareholders committee take secretary board directors board committees board directors chairmansnomination committee board committees remuneration committee corporate governance sustainability committee audit committee board directors members nationality malaysia france austria female switzerland male us germany years years years years years years age tenure average tenure incl ceo years excl ceo incl dual citizen triple citizen calculated year first election corporate governance roche composition name year birth first elected board directors dr christoph franz c e g chairman andr hoffmann c e g vicechairman representative shareholder group pooled voting rights dr jrg duschmal b e g representative shareholder group pooled voting rights dr patrick frost b c e g anita hauser e g prof dr richard p lifton c e g dr jemilah mahmood e g bernard poussot c e g dr severin schwan f dr claudia suessmuth dyckerhoff b e g secretary dr annette luther board directors curricula vitae cvs members board directors current members httpswwwrochecomaboutgovernanceboardofdirectors b former members least last five years httpswwwrochecomaboutgovernanceecbodformer c information cvs reporting date december year least last five years httpswwwrochecomaboutgovernancearchivformercvs corporate governance sustainability committee b audit committee c remuneration committee chairmansnomination committee e nonexecutive director f executive director g independent member board directors committee chairperson board directors b c committees andr hoffmann chair dr patrick frost chair andr hoffmann chair dr christoph franz chair anita hauser dr jrg duschmal dr christoph franz andr hoffmann dr jemilah mahmood dr claudia suessmuth dyckerhoff dr patrick frost dr claudia suessmuth dyckerhoff prof dr richard p lifton bernard poussot corporate executive committee memberships corporate executive worked different countries committee remained unchanged leadership functions became ceo diagnostics division member william pao head roche pharma research corporate executive committee august early development pred member enlarged corporate executive committee left announced october effective roche march new opportunity january matt sause former head united states roche diagnostics north america region became ceo roche diagnostics member prof dr hans clevers joined board corporate executive committee matt sause began directors stepped position career roche indianapolis united states appointed new head roche pred progressed numerous leadership effective march became member roles multiple countries including japan taiwan enlarged corporate executive committee ireland peru south korea joined reporting directly roches group ceo genentech assuming role regional head roche diagnostics north america announced july board directors holds bachelors degree microbiology decided propose roches group ceo dr severin schwan new chairman agm bill anderson ceo roche pharmaceuticals march time dr schwan member corporate executive committee resign member corporate executive decided pursue opportunities outside roche committee since ceo roche effective december dr thomas schinecker group since became ad interim ceo roche pharmaceuticals starting january effective march board directors appointed dr thomas schinecker currently information member corporate ceo diagnostics division dr schwans executive committee enlarged corporate successor ceo roche group dr schinecker executive committee listed see also grew asia earned phd molecular board directors biology united states since joining roche corporate executive committee corporate executive committee corporate executive committee ceo roche ceo roche ceo roche chief financial chief people group pharmaceuticals diagnostics information officer officer enlarged corporate executive enlarged corporate executive committee committee gred pred pharma partnering communications general counselcorporate governance roche composition name year birth position since corporate executive committee dr severin schwan ceo roche group bill anderson ceo roche pharmaceuticals dr thomas schinecker ceo roche diagnostics dr alan hippe chief financial information officer cristina wilbur chief people officer enlarged corporate dr aviv regev head genentech research executive committee early development gred prof dr hans clevers head roche pharma research early development pred dr james h sabry global head pharma partnering barbara schdler head group communications claudia bckstiegel general counsel secretary corporate perolof attinger executive committee statutory auditors kpmg klynveld peat marwick goerdeler sa reporting years roche holding ltd kpmg ag since auditor charge john morris ian starkey mark baillache franois rouiller since chief compliance officer pascale schmidt curricula vitae cvs members corporate executive committee enlarged corporate executive committee current members httpswwwrochecomaboutgovernanceexecutivecommittee b former members least five years back httpswwwrochecomaboutgovernanceecbodformer c information cvs reporting date december year least last five years httpswwwrochecomaboutgovernancearchivformercvs group structure shareholders roches operating businesses organised information roche holding ltd significant two divisions pharmaceuticals diagnostics subsidiaries associated companies including company name listing information domicile share pharmaceuticals division comprises capital equity interest listed finance two business segments roche pharmaceuticals report note roche group consolidated including genentech united states financial statements list subsidiaries chugai associates diagnostics division replaced major shareholders listed finance previous business area structure four report notes roche group business areas new customer areas sales consolidated financial statements equity presented following customer areas attributable roche shareholders related core lab molecular lab point care pathology parties pages note lab diabetes care details see finance report financial statements roche holding ltd significant shareholders addition significant shareholders published business activities carried group relevant webpage see link subsidiaries associated companies detailed disclosure office six exchange regulation roche pharmaceuticals incl genentech pharmaceuticals chugai core lab molecular lab diagnostics point care pathology lab diabetes care composition six exchange regulation httpswwwseragcomenresourcesnotificationsmarketparticipantssignificantshareholdershtmlcorporate governance roche andr hoffmann chairman corporate governance sustainability committee remuneration committee dr jrg duschmal member audit committee andr hoffmann vicechairman board directors chairman remuneration committee boards corporate governance sustainability committee member boards chairmansnomination committee dr jrg duschmal member board directors boards audit committee serve respective capacities board committees representatives shareholder group pooled voting rights receive remuneration set forth remuneration report finance report note roche group consolidated financial statements related parties relationships exist shareholders pooled voting rights crossshareholdings capital structure information roches capital structure provided earnings liquidation proceeds following finance report notes financial repayment share capital roches nes statements roche holding ltd rights pertaining thereto including provisions additional details contained articles protecting interests nes holders incorporation roche holding ltd described articles incorporation roche holding ltd movement recognised amounts last three financial years detailed finance information debt instruments report notes financial statements issued outstanding bonds provided roche holding ltd finance report note roche group consolidated financial statements debt extraordinary general meeting held november shareholders agreed information employee stock options provided reduce companys share capital finance report note roche chf chf group consolidated financial statements equity cancellation shares compensation plans including detailed repurchased company novartis information stocksettled stock appreciation holding ag pursuant repurchase agreement rights ssars plan restricted stock units dated november share capital rsus plan roche connect roche divided fully paid bearer shares option plan nominal value chf restrictions exercise voting rights roche issued options apart employee bearer shares stock options described finance report note roche group consolidated authorised conditional capital financial statements equity compensation plans options issued connection addition nonvoting equity debt instruments securities nes issued bearer form form part share capital neither options awarded employees confer voting rights nes confers debt instruments issued rights one share participate available effect roches share capital httpswwwrochecomaboutgovernancearticleofincorporationcorporate governance roche board directors corporate executive committee information member board directors independence definition based directors member corporate definition swiss code best practice executive committee listed pages corporate governance economiesuisse members board directors age limit complemented specific preceding criteria restriction term office see httpswwwrochecomaboutgovernance boardofdirectors curricula vitae cvs current former members least last five years bodies principles governance principles information including information delegation competence reservation powers years first election board memberships management group companies additional positions memberships activities executive bodies company include available continuously updated internet economic environmental social topics addition status cvs bodies principles together internal organisation relevant reporting date december board directors division authority least last five years separately available responsibilities board management remits board committees rules pursuant article para point vegv information control mechanisms number permitted activities board available board dealings corporate directors corporate executive committee management governed bylaws members outlined articles incorporation roche holding ltd board directors roche holding ltd organised ensure group conducts since annual general meeting elected businesses responsibly focus members board directors chairman longterm value creation end roche board directors members board delegated certain responsibilities remuneration committee annual basis several committees composition elections nominee voted chairpersons december described separately see articles incorporation pages committees authorities roche holding ltd minutes responsibilities defined detail th ordinary annual general meeting roche bylaws board directors holding ltd held march committees chaired independent exception dr severin schwan none directors members board directors office end member roches according bylaws board directors corporate executive committee served board meeting may convened without executive capacity group subsidiary chairman present request five financial years preceding current members roche board meets year reporting period lack existing assess chairmans performance meeting business connections group attended chairman chaired group subsidiary independent roches board vicechairman httpswwwrochecomaboutgovernanceboardofdirectors httpswwwrochecomaboutgovernanceexecutivecommittee httpswwwrochecomaboutgovernancearticleofincorporation httpswwwrochecomaboutgovernanceannualgeneralmeetings httpswwwrochecomaboutgovernancearticleofincorporation httpswwwrochecomaboutgovernancecommittees httpswwwrochecomaboutgovernancearticleofincorporation board directors board directors board committees board committees chairmansnomination committee remuneration committee corporate governance sustainability committee audit committee corporate executive committee corporate executive committee ceo roche ceo roche ceo roche chief financial chief people group pharmaceuticals diagnostics information officer officer part management information dialogues consolidated group risk report system mis board access including target risk profile discussed electronic information platform provides corporate executive committee approved timely information board directors together group business plan material board committees system risks reviewed board yearly basis controls set forth effectiveness risk management process monitored group risk advisory team board directors established system overall process regularly reviewed controls continuously monitored external auditors findings presented audit committee corporate governance audit committee full board details sustainability committee board risk management risk management policy directors consists following elements see risk management website financial report operating financial risks risk risk management specifically described management system finance report roche group established risk system internal controls financial reporting management process covering entire company see finance report system place identify manage internal audit types risks opportunities potentially group audit reports administrativelyto general affecting business including economic counsel direct access gives regular environmental social impacts board briefings audit committee corporate directors highest governance body involved governance sustainability committee roches risk management policy sets chairman board directors approach accompanying responsibilities ongoing activities audit reports chief roches pharmaceuticals diagnostics audit risk advisory executive attends audit divisions global functions conduct formal committee partly corporate governance assessment process least year sustainability committee meetings must develop risk plans material external auditors group audit independent risks opportunities monitored appraisal function evaluates reviews deviations reviewed regular performance groups activities service board httpswwwrochecomaboutsustainabilityapproachriskmanagement additional information provided finance report note roche group consolidated financial statements risk management corporate governance roche directors management annual following blackout periods arewere effect audit plan yearly defined focus areas eg respectively commercial activities distributor management healthcare compliance validated senior blackout periods management approved audit committee roche group committed december december maintaining high standard internal control february february throughout worldwide operations management april april april april responsible assessing business risks june july june july aspects operation implementing october october effective efficient processes controls october october whilst ensuring compliance internal external rules regulations conducting operational audits group audit determines blackout periods changed chairman managements response risks surrounding board directors circumstances warrant business processes systems evaluates appropriateness completeness efficiency roche employees involved preparation processes controls action plans regular publicity events particular annual implement necessary changes enhancements halfyear reports media conferences developed together businessauditee quarterly sales releases otherwise tracked completion access potentially share price sensitive statutory auditors see information roche subject black chief compliance officer compliance periods irrespective whether relevant officers subsidiaries see information share price sensitive roche safety security health environmental blackout periods persons protection department shall keep relevant information confidential corporate sustainability steering committee must disclose noninsider within science ethics advisory group seag outside roche including family members ii buy sell otherwise trade equity securities members corporate executive committee roche shares nonvoting equity securities invited attend meetings board nes well options similar instruments directors report person derivatives based thereon iii provide agenda items concerning situation trading recommendations thereon automatic warrants members enlarged corporate execution predefined periodic purchase orders executive committee may also invited attend roche connect programme board committees invite chairman subject blackout periods board corporate executive committee members deliver reports committee meetings addressees scope exceptions may elect commission independent expert regard blackout periods please refer reports call services consultants roche group insider directive httpsassets cwprochecomfxebgroup year several blackout periods imposed insiderpolicypdf members board directors senior managers certain employees prohibited trading company stock httpswwwrochecomaboutsustainabilityenvironment httpswwwrochecomaboutsustainability httpswwwrochecominnovationethicalstandardsadvisory dr patrick frost chairman audit committee board directors met meetings meetings hours length including fullday meeting addition board went day trip european affiliate board committees met follows chairmansnomination committee meetings approx hours remuneration committee meetings approx hours audit committee meetings approx hours corporate governance sustainability committee meetings approx hours board directors regularly conducts assessment selfassessment assessment third parties via electronic survey personal interviews performance assessment third party board assessment performed whereby designated new chairman board directors conducted personal interviews members board directors members corporate executive committee maximum ordinary notice period twelve months changeofcontrol clauses employment contracts management contracts fall within scope subsection annex six directive information relating corporate governance remuneration committee members recuse deliberations decisions matters affect interests figures indicate actual length meetings include directors extensive premeeting preparations postmeeting followup activitiescorporate governance roche attendance board board committee meetings corporate governance chairmans nomination remuneration audit sustainability board committee committee committee committee number meetings c franz hoffmann j duschmal p frost hauser r p lifton j mahmood member board since march b poussot schwan c suessmuth dyckerhoff p bulcke member board march h clevers member board march j brown member board september member committee member since march member march member september remuneration shareholdings loans details regarding remuneration shareholdings rules aoi loans content method determining content board cec compensation shareholding programmes rules principles basic principles elements compensation applicable performance shareholding programmes serving former related pay members board directors corporate rules principles executive committee together description allocation equity securities authorities procedure determining convertible rights options set forth separate remuneration report additional amount pages finance report payments members notes roche group consolidated executive committee financial statements equity attributable roche appointed vote shareholders related parties pages pay annual general listed note financial meeting shareholders statements roche holding ltd board rules loans credit facilities executive shareholdings postemployment benefits rules vote pay following rules remuneration shareholdings agm loans board directors board corporate executive committee cec set forth articles incorporation aoi httpswwwrochecomaboutgovernancearticleofincorporationcorporate governance roche participatory rights shareholders participatory rights shareholders articles incorporation defined roches articles incorporation shareholders representing shares nominal roche shares issued bearer value least chf million request restrictions admission annual general placement items agenda annual meetings exception shares must general meeting must done later deposited within specified period days date meeting date meeting admittance card must issued shareholders name provided rules issue instructions articles incorporation shareholder independent proxy rules electronic elect represented third party participation annual general meeting annual general meeting laid corresponding invitation annual general meeting regulated articles incorporation contain restrictions articles incorporation exercise voting rights quorum requirements stipulated conformity swiss code obligations change control defensive measures articles incorporation contain provisions nonvoting equity securities would terminated mandatory bid rule swiss law applies event acquisition vesting period restrictions preexisting awards would changeofcontrol clauses removed options could components remuneration based roche exercised immediately httpswwwrochecomaboutgovernancearticleofincorporation relationship statutory auditors annual general meeting roche holding ltd auditors direct access audit march shareholders voted committee chair well head appoint kpmg ag kpmg statutory auditors group audit discuss relevant issues based existing legal requirements swiss reports statutory auditor code obligations article concerning consolidated financial statements maximum term office seven years auditor financial statements found pages charge franois rouiller auditor respectively finance report charge since business year information long auditor charge serving kpmg received following remuneration capacity provided services statutory auditors roche holding ltd auditors roche companies statutory auditors participate audit including chugai committee meetings prepare written oral reports results audits audit committee oversees assesses auditors millions chf makes recommendations board auditing services information authorities responsibilities auditrelated services audit committee see article assurance bylaws statutory auditors participated nonstatutory audits five meetings audit committee tax services services performance kpmg assessed based total different elements affiliate surveys evaluate service level country level interviews roche key stakeholders audit fee reviewed head group audit selfevaluation kpmg internal processes approved audit committee every year ensure compliance federal audit oversight takes consideration changes roches authority faoa audit committee guide business well changes financial reporting audit standards regulations kpmgs independence ensured limiting kpmg providing certain nonaudit services statutory auditors elected year furthermore permitted services exceed annual general meeting total audit fee unless explicitly rewieved approved audit committee auditing services provided legally required company formal policy governing engagement statutory auditor nonaudit auditrelated services include assurance services limits certain permitted accounting services provided auditors services agreed audit committee necessarily provided statutory potential nonaudit service engagement auditor services go beyond legal reviewed policy authority requirements could include attestation proceed given services comfort letters consultations httpswwwrochecomaboutgovernancearticleofincorporationcorporate governance roche tax services include services respect rfi culminated shortlisting two audit compliance tax returns tax advice except firms invited request proposal services related audit tax rfp phase rfp phase completed services include advice relating process phases audit tender conducted improvements regulations trainings involvement key stakeholders thorough independent process line external audit services tender predefined evaluation criteria audit firms upon initiative roche audit committee provided appropriate access roche management four audit firms invited participate relevant financial nonfinancial tender external auditing services starting information relevant respective proposals financial year based assessment audit firms project team managed tender process part tender process board directors two phases request information rfi phase proposes shareholders reappoint kpmg conducted throughout course external auditor financial year relationship independent proxy since testaris ag served general meeting period independent proxy annual general conclusion ordinary annual meeting march shareholders elected general meeting shareholders testaris ag independent proxy period conclusion ordinary rules issue instructions annual general meeting shareholders testaris ag independent proxy rules electronic paid services annual general participation annual general meeting meeting according expenditure totalling laid corresponding invitation chf chf ordinary annual general meeting regulated extraordinary annual general meeting articles incorporation board directors nominates testaris ag election independent proxy annual information policy provided articles incorporation presentations analyst investor conferences corporate notices published swiss available internet publications official gazette commerce daily available newspapers designated board directors httpswwwrochecompublications basler zeitung finanz und wirtschaft lagefi ordered email le temps neue zrcher zeitung materialsmanagementmmrochecom fax roche reports halfyear fullyear results business reports published print andor online contact address investor relations formats media events addition detailed f hoffmannla roche ltd investor relations firstquarter nine months sales figures group finance basel switzerland published year april october tel current list publication dates available fax internet additional information including details relevant information documents including specific contact persons available media releases investor updates internet httpswwwrochecomaboutgovernancearticleofincorporation httpswwwrochecommedia httpswwwrochecominvestors httpswwwrochecomcontactinvestorcontactscorporate governance roche chief compliance officer compliance officers network chief compliance officer compliance may reach line managers local officers network committed ensuring compliance officer chief compliance officer roche group code conduct consistently contact roche group code conduct complied throughout roche group help advice line compliance tool also serves chief compliance officer also serves contact platform ideas suggestions concerning person shareholders employees business documents partners customers suppliers general public issues relating implementation addition roche established business compliance code ethics incident management system beims enables line management compliance employees parties become aware officers chief compliance officer violations roche group code conduct capture track monitor alleged violations bring attention managers initial reports resolution supervisors local compliance officer report chief compliance officer business ethics incidents recorded ms pascale schmidt system internal investigations team email pascaleschmidtrochecom regionallocal management receives specific tel disclosures concrete information alleged violation treated confidentially addition employees roche group code conduct one third parties may anonymously report irregularities certain predefined categories corporate complaints mother tongue via roche governance sustainability committee group speakup line part continuous audit committee board directors enhancement roches human rights programme regularly informed substantial violations compliance applicable laws managements corrective actions taken regulations interested party report allegations channel believe chief compliance officer reports good faith actual potential human right general counsel also submits regular reports violation occurred roche roches value corporate governance sustainability chain case questions uncertainties committee needed audit committee interpretation roche group code board directors conduct reference documents employees nonapplicabilitynegative disclosure expressly noted information negative declaration provided contained mentioned herein either six swiss exchange corporate governance nonapplicable omission construed directive commentary thereto httpswwwrochecomaboutgovernancecodeofconduct httpswwwrochecomaboutgovernancecodeofconductcomplianceofficer httpswwwrochecomaboutgovernancecodeofconductremuneration report roche remuneration report employees compensated fairly transparently competitively participate appropriately companys success optimal conditions enable employees make best possible contribution improving healthcare patients principles motivation expertise performance transparent compensation structure ensure employees key success roche compensation packages competitive innovative agile company conviction structure individual components forms basis compensation policy regularly benchmarked based relevant swiss european international market criteria roche aims remunerate employees fairly remuneration guidelines underlying transparently line market conditions principles also subject regular outside enable participate appropriately comparisons companys success pursue goal providing equitable competitive performance however compensation policy one based resultsoriented compensation factor safeguarding roches future success key element corporate culture strive balanced mix fixed variable offers employees conditions compensation components geared make best possible contribution employees position management responsibility shared corporate goal improving healthcare patients includes sound firstly variable components intended sustainabilityoriented value system create additional financial incentives achieve based integrity courage passion corporate goals keep innovation time decentralised management consistently high level increasing value approach plays major role wide scope company creates stakeholder individual decisionmaking respectful groups secondly order allow employees interactions openness diversity wideranging managers participate companys training development opportunities business success adequate compensation attractive working environment unidimensional measures key objectives incentivised diminishment questions remuneration would annual bonus payments longterm fall far short securitiesbased programmes roche committed fair performancebased global company like roche market resultsoriented compensation policy competitive remuneration plays key role links employees interests various along performance successbased stakeholder groups roche place work httpscareersrochecomglobalenremuneration report roche remuneration decision process approval framework overview present remuneration committee year remuneration committee roches decides corresponding compensation board directors decides remuneration right say decisions decision board members members groups right reserved remuneration committee corporate executive committee members chairman group ceo members groups corporate executive committee must remuneration decision process approval framework beneficiary remuneration board directors bod corporate executive decision approval components chairman c committee cec incl ceo roche group base pay remuneration bonus c stocksettled stock remuneration committee annual general meeting appreciation rights ssars restricted stock units rsus pension c remuneration committee tracks market data since total aggregate amounts salaries leading global pharmaceutical based decisions submitted companies major swiss companies general meeting approval implementing reports findings full board external ordinance excessive compensation consulting firm pricewaterhousecoopers ag pwc listed jointstock companies verordnung gegen assists remuneration committee roche bermssige vergtungen bei brsenkotierten performing market comparisons advising aktiengesellschaften vegv general meeting pwc awarded additional mandates shall vote annually binding effect roche group information remuneration approval remuneration board committees remit powers procedures directors resolved board directors making remuneration decisions found corporate executive committee details bylaws roche board directors see articles incorporation also outlined sections principles governing specific remuneration components see peer set abbott laboratories abbvie amgen astrazeneca bristolmyers squibb danaher eli lilly glaxosmithkline johnson johnson medtronic merck co novartis novo nordisk pfizer sanofi peer set abb alcon credit suisse holcim lonza nestl richemont ubs zurich httpswwwrochecomaboutgovernancearticleofincorporation httpswwwrochecomaboutgovernancearticleofincorporation abbott laboratories peer set abbvie amgen abb astrazeneca alcon bristolmyers squibb credit suisse danaher holcim eli lilly lonza glaxosmithkline nestl johnson johnson roche richemont medtronic ubs merck co zurich novartis novo nordisk pfizer sanofi peer set market comparison companies salary assessment pharma peer set major swiss companies procedure submitting total board retrospective approval executive remuneration shareholder total aggregate bonus amounts corporate approval annual general meeting executive committee chairman year annual general meeting agm board directors financial year ended shareholders approve total remuneration submitted retrospectively ordinary board directors corporate agm separate binding approval executive committee decided board directors remuneration committee prospective approval board directors respectively board executive aggregate remuneration submitted prospectively according approval agm agm separate binding approval roche committed obtaining separate period two ordinary agms binding shareholder approvals total remuneration paid board directors remuneration report shall submitted corporate executive committee follows advisory vote shareholders agm remuneration report roche andr hoffmann chairman remuneration committee approval total remuneration annual general meeting agm financial year financial year approval total remuneration retrospective c bonus chairman c board directors bod bonus financial year total amount cec corporate executive committee cec including ceo roche group bonus bonus financial year total amount prospective bod base pay remuneration board directors bod including chairman c aggregate total remuneration agm agm base pay remuneration cec corporate executive committee cec including ceo roche group base pay aggregate total remuneration agm agm ssars base pay rsus stocksettled stock appreciation rights ssars indirect benefits restricted stock units rsus indirect benefits advisory vote retrospective remuneration report advisory vote remuneration report agm agm agm agm remuneration components overview remuneration elements performance nonfinancial success thus remuneration members board align interests roche employees directors corporate executive committee shareholders societal environmental composed following elements objectives also taken account fixed base salary complemented lti remuneration components intended annual variable bonus shortterm incentive sustainably homogenously longterm sti perennial remuneration elements oriented perspective align managements interest ssars rsus longterm incentive lti shareholders holders non voting equity securities give participating remuneration components linked managers additional incentive achieve employees performance companys financial sustainable shareholder value growth composition remuneration board directors corporate executive committee board directors corporate executive committee annual remuneration elements description c bod ceo roche group cec base pay monthly payment quarterly remuneration see payments bonus annual payment years years cash see blocked nonvoting blocked nonvoting equity securities equity securities andor shares andor shares pensions etc see perennial remuneration elements stocksettled stock see years appreciation rights additionally ssars blocked nonvoting equity securities exercise restricted stock see years units rsus blocked nonvoting equity securities httpswwwrochecominvestorsreportsperformance httpswwwrochecomaboutsustainabilityenvironmentgoalsperformanceremuneration report roche lti corporate executive committee expiration periods aligned newly enlarged corporate executive issued ssars rsus see unlike committee composed ssars participants two programmes members rsus based already existing individual corporate executive committee target value total lti corporate executive choice determining mix rsus ssars committee members base pay fouryear cliff vesting measured january year vesting corporate executive committee lti mix ssarsrsus fixed base calculation vesting period cliff vesting expiration period based individual target ssars value total lti years years years corporate executive committee members base pay rsus measured january years years year remaining participants ssars offering level choice empowers participants rsus programmes offered yearly basis engage fully total rewards enables choice three combinations determine mix better understand critical element restricted stock units rsus stocksettled compensation increases value stock appreciation rights ssars options used programme instead ssars countries following options available attractively designed roche longterm incentive programme enables roche attract choice choice choice motivate retain best talent keep ssars ssars ssars aligned companys longterm success rsus rsus rsus fixed base salary indirect benefits employer contribution roche pensions insurance contributions sti remuneration roche connect bonus tax consulting services components lti expense allowances stocksettled stock appreciation rights restricted stock units others childrens schooling costs foreign tax obligation variable longterm ahvivalv employer contribution social securities beneficial parts base pay fixed bonuses variable base pay cash payment determined bonuses annually awarded individual position based salary market data contributions value creation business year leading global pharmaceutical companies see meant incentive strive footnote major swiss companies outstanding results create new business see footnote reflects individuals abilities opportunities bonus amounts linked group experience performance time pay divisional core profits sales growth constant adjustments likewise linked individual exchange rates operating profit capital performance take account prevailing charge opac based core operating profit core market conditions companys overall earnings per share nonvoting equity security financial situation nes growth constant exchange rates product development pipeline diversity employees remuneration committee makes reviews managers environmental goals additionally final decision individual base pay paid linked achievement measurable chairman board directors qualitative individual functional performance members corporate executive committee objectives competitive reasons roche remuneration members disclose individual performance objectives board members corporate executive committee chairman httpscareersrochecomglobalendiversityandinclusion httpswwwrochecomaboutsustainabilityenvironmentgoalsperformance goals roche group httpsassetscwprochecomfxfshegoalscommunicationpdfremuneration report roche december end reporting year restricted stock units rsus longterm january following reporting year proportion restricted stock units rsus remuneration committee decides bonuses members corporate executive committee amounts payable chairman total lti based individual board members corporate executive target value total lti corporate executive committee respect relevant reporting year committee members base pay based performance aforementioned measured january year objectives time remuneration committee also decides form bonuses rsus contain rights receive nonvoting equity awarded ie cash payments andor blocked securities andor shares fouryear vesting applicable nonvoting equity securities period plus value adjustment amount shares equivalent sum dividend paid vesting period attributable number remuneration committee uses discretion nonvoting equity securities andor shares appropriately weighting criteria individual award granted bonus allocation vested recipient corporate executive committee four years total employees eligible thereafter resulting nonvoting equity bonus roche bonus program securities andor shares may remain blocked ten years stocksettled stock appreciation rights ssars longterm rsu awards allocated individually ssars proportion lti corporate corporate executive committee executive committee based remuneration committees discretion individual target value total lti corporate executive committee members rsus served remuneration component base pay measured january year eligible roche employees ssars entitle holders benefit financially indirect benefits increase value roches nonvoting shown ceo roche group equity securities grant date chairman respectively members exercise date ssars granted vest together corporate executive committee additionally four years exercised within received indirect benefits pension funds insurance ten years grant date unexercised ssars contributions roche connect payments foreign lapse without compensation since fair tax obligation tax consulting services value ssars calculated grant annual expense allowances shown date using trinomial model american call individual members corporate executive options details see committee received payments family children education allowances schooling costs ssars corporate executive committee children allocated individually remuneration committees discretion total employees received ssars weighting fixed variable longterm remuneration components target percentage total remuneration chairman board directors corporate executive committee including ceo roche group fixed variable longterm variable longterm remuneration paid members corporate executive committee ranged total compensation ratio variable remuneration components relative fixed base pay corporate executive committee ratio variable remuneration components bonuses ssars rsus relative value fixed base pay lti longterm sti variable total criteria bonus ssars total lti rsus total lti individual target value minimum maximum performance criteria group objectives group divisional business value development value development performance individual objectives considering determined determined core profits sales growth constant exchange rates performance performance plus operating profit capital charge opac based nes grant value adjustment core operating profit core earnings per share dividends nonvoting equity security nes growth constant nes grant exchange rates product development pipeline diversity employees managers environmental goals split group objectives na na b individual objectives na na weighting criteria remuneration committees discretion decision objectives na applicable assessed consideration performance competitors macroeconomic development based already existing individual target value total lti corporate executive committee members base pay measured january year details please refer following sections remuneration report see also finance report note roche group consolidated financial statements related parties note financial statements roche holding ltd board executive shareholdings remuneration board directors resolution approval form quarterly fixed cash payments remuneration chairman board shown remuneration members directors members board directors board directors table decided remuneration committees board activities roche paid discretion taking account market comparisons employers contributions totalling chf chf social security agencies remuneration form cash payments members board directors beside annually tracked market data directors legally required contributions separately pay leading global pharmaceutical stated chairman board directors companies see footnote major swiss companies see footnote assisted basic remuneration board directors consultancy pwc excluding chairman remained unchanged since previous years board directors separately submit total aggregate exception chairman board bonus chairman board directors directors bonus form blocked shares financial year general meeting dr severin schwan executive member retrospective binding approval board members board directors awarded shares nonvoting equity securities maximum amounts total aggregate ssars remuneration board directors period ordinary general meeting loans credits granted ordinary general meeting members board directors tabled separately previous years general meetings prospective binding advisory service genentech approval see scientific resource board prof dr richard p lifton received honoraria amounting total amount remuneration members usd chf board directors members board directors received remuneration additional compensation list members positions committee memberships chairmanships see detidua remuneration report roche remuneration members board directors chf additional remuneration additional special additional basic remuneration committee memberschairs remuneration bvg costs total remuneration c franz chairman see total remuneration paid chairman board directors hoffmann vicechairman j duschmal p frost hauser r p lifton see j mahmood since march b poussot schwan see highest total remuneration paid dr severin schwan member corporate executive committee remuneration received primary function ceo roche group reflected total remuneration corporate executive committee c suessmuth dyckerhoff members march september p bulcke march h clevers march j brown september total costs provisions swiss federal occupational old age survivors invalidity pension act bvg accordance minimum requirements insurance benefits bvg half costs four members board directors subject compulsory insurance borne company exception members chairmans committee chairman vicechairman board members receive chf year committee serve chf year committee chair remuneration serving vicechairman board p rorated remuneration period march december prorated remuneration period january march january september respectively dditionally employer contribution ahvivalv totalling chf including chairman paid form part remuneration detidua remuneration members board directors chf additional remuneration additional special additional basic remuneration committee memberschairs remuneration bvg costs total remuneration c franz chairman see total remuneration paid chairman board directors hoffmann vicechairman j brown p bulcke h clevers j duschmal p frost hauser r p lifton b poussot schwan see highest total remuneration paid dr severin schwan member corporate executive committee remuneration received primary function ceo roche group reflected total remuneration corporate executive committee c suessmuth dyckerhoff total costs provisions swiss federal occupational old age survivors invalidity pension act bvg accordance minimum requirements insurance benefits bvg half costs four members board directors subject compulsory insurance borne company w ith exception members chairmans committee chairman vicechairman board members receive chf year committee serve chf year committee chair remuneration serving vicechairman board additionally employer contribution ahvivalv totalling chf including chairman paid form part remuneration total remuneration paid chairman ten years payable march put board directors shareholder binding vote ordinary chairman dr christoph franz received total annual general meeting agm remuneration shown remuneration committees bonus proposal chairmans total remuneration contained adopted late respect total remuneration board directors financial year form shares blocked detidua remuneration report roche total remuneration paid board board remuneration subject approval directors annual general meeting calendar year members board directors received remuneration including submission chairmans total bonuses employer contribution social aggregate bonus binding vote securities beneficial parts totalling chf annual general meeting chf excluding additional remuneration chairman board employers contribution paid social securities directors includes bonus award chf totalling chf chf form shares blocked ten years shown table section total remuneration remuneration paid former members paid chairman board directors board directors board directors submit remuneration remuneration paid committees bonus proposal adopted late chairman board dr christoph franz respect financial year payable march excluding legally required employers contributions ahvivalv shareholder binding vote ordinary annual general meeting detidua total remuneration paid chairman board directors chf base salary cash tax equalisation pension fund corrections na bonus subject approval annual general meeting pension funds insurances annual expense allowances tax social security including employer contribution social securities beneficial parts total na applicable form shares blocked years calculation number shares based price date transfer march respectively approval agm agm respectively calculation value consideration reduction value due blocking period years reduced market value submitted shareholder approval agm approved agm respectively dditionally employer contribution ahvivalv chf chf paid form part remuneration detidua remuneration report roche retrospective approvals chairmans total aggregate bonus chf proposal agm agm agm aggregate amount aggregate amount aggregate amount financial year financial year financial year total aggregate amount proposal approval approved agm excluding legally required employers contributions ahvivalv bonus award form shares blocked years calculation number shares based price date transfer march march march respectively approval agm agm agm respectively calculation value consideration reduction value due blocking period years reduced market value submitted shareholder approval agm approved agm agm respectively submission boards total chf excluding legally aggregate future remuneration binding required employers contributions ahvivalv shareholder vote excluding bonuses period ending board directors proposes ordinary agm ordinary agm approve board remuneration totalling prospective approvals boards total aggregate future remuneration chf proposal agm agm agm aggregate amount aggregate amount aggregate amount period period period agm agm agm agm agm agm total aggregate amount proposal approval approved agm excluding legally required employers contributions ahvivalv excluding bonuses reconciliation reported excluding bonuses period ending remuneration shareholders ordinary agm approved remuneration members board directors comparison ordinary agm ordinary agm approved board ordinary agm actual remuneration remuneration totalling amounted chf excluding legally chf excluding legally required required employers contributions ahvivalv employers contributions ahvivalv excluding bonuses prospectively approved total remuneration members board directors comparison actual total payments made chf total remuneration total remuneration total remuneration period period period agm agm agm agm agm agm maximum total remuneration approved agm actual total remuneration paid calculation end period within approved limit calculation end period yes yes excluding legally required employers contributions ahvivalv excluding bonuses security holdings statements related parties directors andr hoffmann dr jrg duschmal note financial statements members founders families roche holding ltd significant shareholders closely associated belong addition december contractually bound shareholder group december respectively pooled voting rights end members board directors persons group held shares issued closely associated held roche shares shares detailed information group nonvoting equity securities nes american found finance report note depositary receipts adrs shown roche group consolidated financial table security holdings security holdings shares nes december december nonvoting close nonvoting close equity relatives equity relatives securities others security securities others security shares nes number holdings shares nes number holdings number number type numbertype number number type numbertype board directors c franz hoffmann j duschmal p frost hauser nes nes r p lifton adrs adrs j mahmood na na na na b poussot schwan see security holdings see security holdings corporate executive committee corporate executive committee c suessmuth dyckerhoff total adrs nes adrs nes na applicable shares held shareholder group pooled voting rights listed jointly held close relative r oches adr american depositary receipt listed otcqx httpswwwotcmarketscomstockrhhbyquote international premier symbol rhhby isin us traded usd eight adrs represent one underlying nesremuneration report roche remuneration corporate executive committee resolution approval amount remuneration members remuneration members corporate corporate executive committee executive committee decided general provisions assigning authority remuneration committees discretion taking decisions corporate executive committee account market comparisons remuneration remuneration committee board directors outlined previous years board remuneration decision process directors separately submit total aggregate approval framework bonuses corporate executive committee financial year general meeting members corporate executive retrospective binding approval committee received remuneration work shown amount remuneration maximum amounts total aggregate ceo roche group dr severin schwan remuneration corporate executive explained detail committee period ordinary general meeting ordinary general meeting tabled separately previous years general meetings prospective binding approval see highest total remuneration paid reflected highest total remuneration paid dr severin schwan member member corporate executive committee corporate executive committee see included total amount dr severin schwan executive member paid corporate executive committee see board directors received remuneration total remuneration paid members primary function ceo roche group corporate executive committee highest total remuneration paid dr severin schwan member corporate executive committee chf base salary bonus subject approval total aggregate bonuses corporate executive committee annual general meeting ssars rsus roche connect pension funds insurances payments incl expense allowance tax consulting services total calculation value nonvoting equity securities shares consideration reduction value due blocking period years reduced market value ncluding employer contribution social securities beneficial parts detailed calculation remuneration see annual report shares blocked years calculation number shares based share price date transfer march approval agm sars number grant value according trinomial model american call options chf trinomial model american call options value described stocksettled stock appreciation rights ssars members corporate executive committee ssars blocked years may thereafter exercised whilst exercising resulting nes automatically blocked additional years calculation value nonvoting equity securities consideration reduction value due additional blocking period years reduced market value ssars number grant value according trinomial model american call options chf trinomial model american call options value described stocksettled stock appreciation rights ssars members corporate executive committee ssars blocked years may thereafter exercised whilst exercising resulting nes automatically blocked additional years calculation value nonvoting equity securities consideration reduction value due additional blocking period years reduced market value calculation rsus value number rsus multiplied grant value chf nes closing price grant date march per rsu calculation rsus value number rsus multiplied grant value chf nes closing price grant date march per rsu includes annual expense allowance chf payments tax consulting services chf chf family children education allowance chf chf additionally employer contribution ahvivalv chf chf paid form part remuneration base pay members corporate executive committee base pay chf b anderson hippe schinecker c wilbur total detidua detidua bonuses members bonuses brought forward binding corporate executive committee vote annual general meeting remuneration committee board directors determined corporate executive except dr severin schwan members committee members bonuses based corporate executive committee receive performance agreed objectives bonus cash payment dr severin remuneration committee uses discretion schwan receive bonus form roche appropriately weighting criteria shares blocked ten years see bonus allocation total aggregate amount bonus payment due march bonus chf subject approval total aggregate bonuses corporate executive committee annual general meeting b anderson hippe schinecker c wilbur total detidua remuneration report roche stocksettled stock appreciation already existing individual target value rights ssars members total lti corporate executive committee corporate executive committee members base pay measured ssars members corporate executive january year committee allocated individually remuneration committees discretion ssars fair value ssars calculated shown ssars table grant date using trinomial model american entitle holders benefit financially call options trinomial model effective increase value roches nonvoting equity method valuation american call options securities nes grant date considers possibility exercising option exercise date strike price ssars time prior maturity called american option terms multiyear plan closing price compared european option roche nes grant date ssars since vest allows exercise maturity date four previously granted ssars three years grant date vested ssars exercised numbers ssars strike prices expiry converted nes within ten previously granted dates grant values ssars shown ssars within seven years grant date ssars table unexercised ssars lapse without compensation numbers ssars calculated time issue entered values since ssars proportion lti tables corporate executive committee based information trinomial model american call options please refer boyle phelim p lattice framework option pricing two state variables journal financial quantitative analysis volume issue mar httpsassetscwprochecomfxefde trinomialmodelpdf restricted stock units rsus rsus contain rights receive nonvoting equity members corporate securities andor shares since newly executive committee defined fouryear vesting period plus value since proportion restricted stock units adjustment amount equivalent rsus members corporate executive sum dividend paid vesting period committee total lti based attributable number nonvoting equity already existing individual target value total securities andor shares individual lti corporate executive committee members award granted vested base pay measured january recipient corporate executive committee year rsu awards allocated individually four years thereafter resulting corporate executive committee nonvoting equity securities andor shares may remuneration committees discretion remain blocked ten years detidua detidua stocksettled stock appreciation rights ssars grant value per grant value per number ssar chf value chf number ssar chf value chf b anderson hippe schinecker c wilbur total price chf expiry date price chf expiry date restricted stock units rsus value grant value grant number chf value chf number chf value chf b anderson hippe schinecker c wilbur total calculation value consideration reduction value due additional blocking period years reduced market value indirect benefits members roche nonvoting equity securities nes corporate executive committee amount equal annual salary employer contributions made social discount nes purchased plan security schemes pension plans groupwide subject holding period four years employee stock purchase plan roche connect switzerland respect members corporate executive committee shown indirect benefits addition members corporate executive employer contributions table committee received annual expense allowances table members payments foreign tax obligations tax consulting services shown roche connect voluntary stock purchase table plan offering employees opportunity buy detidua indirect benefits employer contributions chf payments payments annual tax tax annual tax tax pension funds expense roche consulting pension funds expense roche consulting insurances allowances connect services insurances allowances connect services b anderson hippe schinecker c wilbur total including employer contribution social securities beneficial parts detidua detidua remuneration report roche remuneration loans members remuneration former members corporate executive committee corporate executive committee excl ceo roche group payments made meet legal contractual obligations roche paid total chf total remuneration paid members chf individual members corporate executive committee corporate executive committee family calendar year members child education allowances corporate executive committee received remuneration including bonuses employer aforementioned additional payments contribution social securities beneficial parts included total remuneration members totalling chf chf corporate executive committee excluding additional employers contribution paid ahvivalv totalling chf loans credits granted chf form part members corporate executive remuneration committee additional remuneration maximum regular period notice members abovementioned payments paid corporate executive committee months current former members corporate changeofcontrol clauses executive committee employment contracts corporate executive committees shares blocked ten years remuneration subject approval members corporate executive annual general meeting committee cash payment see totalling chf respect submission corporate executive financial year chf excluding committees total aggregate bonuses legally required employers contributions binding vote annual general meeting social security agencies submit board directors proposes awarding proposed total amount ordinary annual members corporate executive committee general meeting agm binding vote bonuses dr severin schwan form roche retrospective approvals members corporate executive committees total aggregate bonuses chf proposal agm agm agm aggregate amount aggregate amount aggregate amount financial year financial year financial year total aggregate amount proposal approval approved agm excluding legally required employers contributions ahvivalv submission corporate executive composed base pay longterm incentives committees total future aggregate ssars calculated grant value without remuneration binding shareholder vote considering reductions value due blocking board directors proposes periods applicable rsus see ordinary agm approve remuneration calculated time reservation nonvoting corporate executive committee totalling equity securities shares without considering chf excluding legally reductions value due blocking periods required employers contributions ahvivalv pension benefits excluding legally required excluding bonuses period ending employers contributions ahvivalv well ordinary agm contributions expenses payments foreign tax obligations tax consulting services amount corporate executive roche connect committees total future aggregate remuneration prospective approvals members corporate executive committees total future aggregate remuneration chf proposal agm agm agm aggregate amount aggregate amount aggregate amount period period period agm agm agm agm agm agm total aggregate amount proposal approval approved agm excluding legally required employers contributions ahvivalv excluding bonusesremuneration report roche reconciliation reported excluding bonuses period ending remuneration shareholders ordinary agm prospectively approved remuneration members corporate executive comparison ordinary agm committee ordinary agm remuneration amounted ordinary agm approved remuneration chf excluding legally required corporate executive committee totalling employers contributions ahvivalv chf excluding legally excluding bonuses required employers contributions ahvivalv prospectively approved total remuneration members corporate executive committee comparison actual total remuneration effected chf amount period amount period amount period agm agm agm agm agm agm maximum total remuneration prospectively approved agm actual total remuneration realised total remuneration calculated end calculation end corresponding agmagm period period agm agm within approved limit calculation end period agm agm yes yes additional amount paid new members corporate executive committee approval agm within approved total amount excluding legally required employers contributions ahvivalv excluding bonuses clawback according ssars plan rules serious addition applicable statutory provisions misconduct participant may include roches longterm incentive plans include inter alia option partially reclaim distributed compensation result special circumstances clawback activity leading serious disciplinary action repeated willful failure perform duties employee voluntarily serves notice reasonably assigned roche termination employment ssars see violation law public regulation rsus see unvested date commission crime termination employment lapse immediately gross negligence willful misconduct without compensation employment engaging conduct bringing disgrace upon termination employment result disrepute roche andor subsidiaries serious misconduct ssars rsus granted violation roches directives outstanding whether vested unvested guidelines relating business conduct shall lapse immediately without compensation guidelines security holdings annual base salary requirement must according guidelines security holdings fulfilled within five years march since members corporate executive case new members within five years committee required hold roche securities start employment members corporate executive committee requirement roche security holdings required hold roche securities equivalent ceo roche group remains unchanged value previously respective annual base salary type security value acquired within five years march case new members within five years start employment ceo roche group shares andor nes annual base salary members corporate executive committee shares andor nes annual base salary security holdings associated held securities shown december december following tables shares nonvoting equity respectively members corporate securities nes ssars restricted stock executive committee persons closely units rsus shares nonvoting equity securities nes december december shares nes close relatives security holdings shares nes close relatives security holdings number number numbertype number number numbertype corporate executive committee shares nes shares nes schwan b anderson hippe schinecker c wilbur total remuneration report roche ssars number ssars held december corporate executive committee schwan b anderson hippe schinecker c wilbur total price chf market price per nes december chf expiry date grant value per ssar chf since trinomial model american call options values according corresponding annual reports restricted stock units rsus number rsus held december corporate executive committee schwan b anderson hippe schinecker c wilbur total grant value per rsu chf chf chf chf nes closing price nes closing price nes closing price nes closing price grant date grant date grant date grant date march march march march general meeting roche holding ltd basel report audit remuneration report opinion statements financial statements audited remuneration report auditors reports thereon roche holding ltd company year ended december audit limited opinion remuneration report information remuneration loans cover information express advances pursuant art ordinance form assurance conclusion thereon excessive remuneration listed companies limited shares verordnung gegen connection audit remuneration bermssige vergtungen bei brsenkotierten report responsibility read aktiengesellschaften vegv sections information consider whether marked grey line audited including information materially inconsistent respective footnotes pages audited financial information remuneration remuneration report report knowledge obtained audit otherwise appears materially misstated opinion information remuneration loans advances remuneration report based work performed complies swiss law art vegv conclude material misstatement information required report basis opinion fact nothing report regard conducted audit accordance swiss law swiss standards auditing sach board directors responsibilities responsibilities provisions remuneration report standards described auditors board directors responsible responsibilities audit remuneration preparation remuneration report report section report independent accordance provisions swiss law company accordance provisions companys articles incorporation swiss law requirements swiss internal control board directors audit profession fulfilled determines necessary enable preparation ethical responsibilities accordance remuneration report free material requirements misstatement whether due fraud error board directors also responsible designing believe audit evidence remuneration system defining individual obtained sufficient appropriate provide remuneration packages basis opinion auditors responsibilities audit information remuneration report board directors responsible objectives obtain reasonable assurance information information comprises whether information remuneration information included annual report loans advances pursuant art vegv include sections marked audited free material misstatement whether due remuneration report consolidated financial fraud error issue auditors reportstatutory auditors report roche includes opinion reasonable assurance btain understanding internal control high level assurance guarantee relevant audit order design audit audit conducted accordance swiss procedures appropriate law sach always detect material circumstances purpose misstatement exists misstatements expressing opinion effectiveness arise fraud error considered companys internal control material individually aggregate e valuate appropriateness accounting could reasonably expected influence policies used reasonableness economic decisions users taken basis accounting estimates related remuneration report disclosures made part audit accordance swiss law communicate board directors sach exercise professional judgement relevant committee regarding among maintain professional scepticism throughout matters planned scope timing audit also audit significant audit findings including dentify assess risks material significant deficiencies internal control misstatement remuneration report identify audit whether due fraud error design perform audit procedures responsive also provide board directors risks obtain audit evidence relevant committee statement sufficient appropriate provide basis complied relevant ethical requirements opinion risk detecting regarding independence communicate material misstatement resulting fraud relationships matters higher one resulting error may reasonably thought bear fraud may involve collusion forgery intentional independence applicable actions omissions misrepresentations override taken eliminate threats safeguards applied internal control kpmg ag franois rouiller paul nichols licensed audit expert auditor charge basel january kpmg ag grosspeteranlage ch basel kpmg ag swiss corporation subsidiary kpmg holding ag member kpmg global organization independent member firms affiliated kpmg international limited private english company limited guarantee rights reserved independent practitioners limited assurance report selected nonfinancial information corporate governance sustainability committee roche holding ltd basel engaged corporate roche ecobalance energy use governance sustainability committee selected types graphs perform assurance procedures provide limited report assurance selected nonfinancial information key figures tables graphs including greenhouse gas ghg emissions pages except scope roche holding ltd consolidated capital goods purchased goods subsidiaries roche group period services fuel energyrelated activities january december disclosed upstream transportation waste generated annual report report operations use sold products scope subject matter criteria assurance engagement relates limited selected nonfinancial information level assurance selected nonfinancial including ghg emissions prepared information including ghg emissions corporate governance sustainability january december disclosed committee roche holding ltd based report document basis preparation nonfinancial information suitable criteria following selected nonfinancial information available roche website including ghg emissions published httpsastoryblokcomfxcefae report within scope limited nonfinancialreportingmetricsguidelines assurance engagement basisforpreparationpdf following people key figures material inherent limitations aspects disclosed report accuracy completeness selected employees fte employees division nonfinancial information including operating divisional group odg ghg emissions subject inherent limitations graphs report given nature methods determining share women executive positions calculating estimating data addition table report greenhouse gas quantification subject inherent uncertainty incomplete following safety security health scientific knowledge used determine factors environmental protection key figures related values needed combine emissions including ghg emissions scope different gases assurance report scope resulting business travel therefore read connection material aspects disclosed report document basis preparation nonfinancial employee health safety table information used roche group report definitions procedures well pricewaterhousecoopers ag birchstrasse postfach ch zurich telephone wwwpwcch pricewaterhousecoopers ag member global pricewaterhousecoopers network firms separate independent legal entityindependent practitioners limited assurance report roche related thirdparty guidelines used present ethical requirements professional standards selected nonfinancial information applicable legal regulatory requirements corporate governance sustainability practitioners responsibility committees responsibility responsibility perform limited assurance corporate governance sustainability engagement express conclusion committee roche holding ltd responsible selected nonfinancial information including preparation presentation ghg emissions roche group disclosed nonfinancial information including ghg report conducted engagement emissions accordance document accordance international standard basis preparation nonfinancial information assurance engagements isae revised responsibility includes design assurance engagements audits implementation maintenance internal reviews historical financial information control system related preparation international standard assurance engagements selected nonfinancial information free assurance engagements greenhouse material misstatement whether due fraud gas statements isae issued error furthermore corporate governance international auditing assurance standards sustainability committee responsible board standards require plan selection application document perform procedures obtain limited assurance basis preparation nonfinancial information whether anything come attention adequate record keeping causes us believe selected nonfinancial information including ghg independence quality management emissions prepared material aspects independent roche holding ltd accordance document basis accordance international code preparation nonfinancial information ethics professional accountants including international independence standards issued based risk materiality considerations international ethics standards board performed procedures obtain sufficient accountants iesba code fulfilled appropriate assurance evidence ethical responsibilities accordance procedures selected depend assurance iesba code founded fundamental practitioners judgement limited assurance principles integrity objectivity professional engagement isae revised competence due care confidentiality isae substantially less scope professional behaviour reasonable assurance engagement relation risk assessment procedures including pricewaterhousecoopers ag applies international understanding internal control standard quality management procedures performed response assessed requires firm design implement risks consequently nature timing extent operate system quality management including procedures gathering sufficient appropriate policies procedures regarding compliance evidence deliberately limited relative reasonable assurance engagement therefore ssessment processes data less assurance obtained limited assurance consolidation engagement reasonable assurance reviewing management nonfinancial engagement reporting processes people key figures performed following assurance procedures assessing aggregation process data among others roche group level r eview application roche group guidelines believe evidence obtained reviewing application roche group sufficient appropriate provide basis selected nonfinancial reporting guidelines conclusion per document basis preparation nonfinancial information conclusion based work performed nothing ite visits management inquiry come attention causes us believe visiting selected pharmaceuticals selected nonfinancial information diagnostics sites costa rica spain including ghg emissions roche switzerland usa selection group period january based quantitative qualitative criteria december disclosed report interviewing personnel responsible internal prepared material respects accordance nonfinancial reporting data collection document basis preparation sites visited group level nonfinancial information determine understanding application roche groups nonfinancial reporting guidelines intended users purpose report per document basis preparation report prepared nonfinancial information corporate governance sustainability committee roche holding ltd solely ssessment key figures purpose reporting selected performing tests sample basis evidence nonfinancial information including ghg supporting selected people key figures emissions disclosed report eg energy consumption emissions air purpose giving conclusion water usage discharge share women accept assume responsibility legal otherwise executive positions concerning completeness accept liability connection accuracy adequacy consistency purpose report including conclusion may used person r eview documentation analysis relevant report shown whose hands policies principles may come persons shall reviewing relevant documentation sample entitled rely conclusion basis including roche group nonfinancial reporting policies management reporting structures documentationindependent practitioners limited assurance report roche permit disclosure report full combination suitable criteria enable corporate governance sustainability committee demonstrate discharged governance responsibilities commissioning independent assurance report selected nonfinancial information including ghg emissions without assuming accepting responsibility liability third parties part fullest extent permitted law accept assume responsibility anyone corporate governance sustainability committee roche holding ltd work report pricewaterhousecoopers ag christophe bourgoin annina binder zurich february maintenance integrity roche holding ltds website content responsibility corporate governance sustainability committee work carried assurance provider involve consideration maintenance integrity roche holding ltds website accordingly assurance provider accepts responsibility changes may occurred specified nonfinancial information suitable criteria since initially presented websiteimprint cautionary statement regarding statement regarding earnings per share growth forwardlooking statements profit forecast interpreted annual report contains certain forwardlooking mean roches earnings earnings per share statements forwardlooking statements may subsequent period necessarily identified words believes expects match exceed historical published earnings anticipates projects intends seeks earnings per share roche estimates future similar expressions discussion among things strategy goals plans trademarks legally protected intentions various factors may cause actual results differ materially future reflected links thirdparty pages provided convenience forwardlooking statements contained annual express opinion content report pricing product initiatives thirdparty pages expressly disclaim competitors legislative regulatory developments liability thirdparty information use economic conditions delay inability thereof obtaining regulatory approvals bringing products market fluctuations currency exchange rates roche annual report published german general financial market conditions uncertainties english discovery development marketing new products new uses existing products including reporting consists actual annual report without limitation negative results clinical trials finance report contains annual research projects unexpected side effects pipeline financial statements consolidated financial marketed products increased government pricing statements regard content management pressures interruptions production loss report per articles incorporation consists inability obtain adequate protection intellectual aforementioned reports exception property rights litigation loss key executives remuneration report employees adverse publicity news coverage printed nonchlorine bleached fsccertified paperkey dates annual general meeting march firstquarter sales april halfyear results july ninemonth sales october published f hoffmannla roche ltd group communications basel switzerland tel wwwrochecom orderdownload publications internet wwwrochecompublications email materialsmanagementmmrochecom fax media relations tel email mediarelationsrochecom investor relations tel email investorrelationsrochecom corporate sustainability committee tel email corporatesustainabilityrochecomdoing patients need next believe urgent deliver medical solutions right even develop innovations future passionate transforming patients lives courageous decision action believe good business means better world come work day commit scientific rigour unassailable ethics access medical innovations today build better tomorrow proud many working one across functions across companies across world rochef hoffmannla roche ltd basel switzerland trademarks legally protected wwwrochecom